|
DE10214983A1
(de)
|
2002-04-04 |
2004-04-08 |
TransMIT Gesellschaft für Technologietransfer mbH |
Vernebelbare Liposomen und ihre Verwendung zur pulmonalen Applikation von Wirkstoffen
|
|
DE60334618D1
(de)
*
|
2002-06-28 |
2010-12-02 |
Protiva Biotherapeutics Inc |
Verfahren und vorrichtung zur herstellung von liposomen
|
|
US9228186B2
(en)
|
2002-11-14 |
2016-01-05 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
|
WO2005089224A2
(en)
|
2004-03-12 |
2005-09-29 |
Alnylam Pharmaceuticals, Inc. |
iRNA AGENTS TARGETING VEGF
|
|
US20060134189A1
(en)
*
|
2004-11-17 |
2006-06-22 |
Protiva Biotherapeutics, Inc |
siRNA silencing of apolipoprotein B
|
|
US9393315B2
(en)
|
2011-06-08 |
2016-07-19 |
Nitto Denko Corporation |
Compounds for targeting drug delivery and enhancing siRNA activity
|
|
RS63964B1
(sr)
|
2005-08-23 |
2023-03-31 |
Univ Pennsylvania |
Rnk koja sadrži modifikovane nukleozide i postupci za njenu upotrebu
|
|
CN101346393B
(zh)
|
2005-11-02 |
2015-07-22 |
普洛体维生物治疗公司 |
修饰的siRNA分子及其应用
|
|
EP2194128B1
(en)
|
2006-05-11 |
2012-08-01 |
Alnylam Pharmaceuticals Inc. |
Compositions and methods for inhibiting expression of the PCSK9 gene
|
|
US8598333B2
(en)
*
|
2006-05-26 |
2013-12-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA silencing of genes expressed in cancer
|
|
EP2238251B1
(en)
*
|
2007-12-27 |
2015-02-11 |
Protiva Biotherapeutics Inc. |
Silencing of polo-like kinase expression using interfering rna
|
|
WO2009134487A2
(en)
*
|
2008-01-31 |
2009-11-05 |
Alnylam Pharmaceuticals, Inc. |
Optimized methods for delivery of dsrna targeting the pcsk9 gene
|
|
MX2010009611A
(es)
|
2008-03-05 |
2010-12-15 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para inhibir la expresion de genes eg5 y vegf.
|
|
CA2721333C
(en)
|
2008-04-15 |
2020-12-01 |
Protiva Biotherapeutics, Inc. |
Novel lipid formulations for nucleic acid delivery
|
|
CA2730340C
(en)
|
2008-07-14 |
2017-02-07 |
Polypid Ltd. |
Sustained-release drug carrier composition
|
|
EP2334793B1
(en)
|
2008-09-25 |
2016-04-06 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of serum amyloid a gene
|
|
JP5777519B2
(ja)
*
|
2008-10-09 |
2015-09-09 |
テクミラ ファーマシューティカルズ コーポレイション |
改良されたアミノ脂質および核酸の送達方法
|
|
SG10201809460SA
(en)
|
2008-10-20 |
2018-11-29 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expression of transthyretin
|
|
DK2355851T3
(en)
|
2008-11-10 |
2018-06-25 |
Arbutus Biopharma Corp |
Newly known lipids and compositions for release of therapeutic agents
|
|
CA2746514C
(en)
|
2008-12-10 |
2018-11-27 |
Alnylam Pharmaceuticals, Inc. |
Gnaq targeted dsrna compositions and methods for inhibiting expression
|
|
US9132147B2
(en)
*
|
2008-12-31 |
2015-09-15 |
Roche Innovation Center Copenhagen |
Use of LNA ApoB antisense oligomers for the treatment of acute coronary syndromes
|
|
NZ594995A
(en)
*
|
2009-03-12 |
2013-06-28 |
Alnylam Pharmaceuticals Inc |
LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HUMAN KINESIN FAMILY MEMBER 11 (Eg5) AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) GENES
|
|
KR101184928B1
(ko)
*
|
2009-05-14 |
2012-09-20 |
한국과학기술연구원 |
작은 올리고뉴클레오티드의 중합 방법 및 상기 중합 방법에 의하여 제조된 고분자 올리고뉴클레오티드의 용도
|
|
KR20120050429A
(ko)
*
|
2009-06-15 |
2012-05-18 |
알닐람 파마슈티칼스 인코포레이티드 |
Pcsk9 유전자를 표적으로 하는 지질 제형된 dsrna
|
|
US9051567B2
(en)
|
2009-06-15 |
2015-06-09 |
Tekmira Pharmaceuticals Corporation |
Methods for increasing efficacy of lipid formulated siRNA
|
|
DE102009031274A1
(de)
|
2009-06-30 |
2011-01-13 |
Justus-Liebig-Universität Giessen |
Liposomen zur pulmonalen Applikation
|
|
WO2011000108A1
(en)
|
2009-07-01 |
2011-01-06 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing apolipoprotein b
|
|
JP5766188B2
(ja)
|
2009-07-01 |
2015-08-19 |
プロチバ バイオセラピューティクス インコーポレイティッド |
固形腫瘍に治療剤を送達するための脂質製剤
|
|
CN105126179B
(zh)
|
2009-07-14 |
2018-09-25 |
波利皮得有限公司 |
持续释放药物载体组合物
|
|
WO2011011447A1
(en)
|
2009-07-20 |
2011-01-27 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing ebola virus gene expression
|
|
AP2015008874A0
(en)
|
2009-08-14 |
2015-11-30 |
Alnylam Pharmaceuticals Inc |
Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
|
|
EP2467357B1
(en)
|
2009-08-20 |
2016-03-30 |
Sirna Therapeutics, Inc. |
Novel cationic lipids with various head groups for oligonucleotide delivery
|
|
CN102639115A
(zh)
|
2009-09-15 |
2012-08-15 |
阿尔尼拉姆医药品有限公司 |
脂质配制的组合物及抑制eg5和vegf基因的表达的方法
|
|
US9187746B2
(en)
|
2009-09-22 |
2015-11-17 |
Alnylam Pharmaceuticals, Inc. |
Dual targeting siRNA agents
|
|
CA2775092A1
(en)
|
2009-09-23 |
2011-03-31 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing genes expressed in cancer
|
|
WO2011056883A1
(en)
|
2009-11-03 |
2011-05-12 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of transthyretin (ttr)
|
|
EP2496700B1
(en)
|
2009-11-04 |
2017-03-01 |
The University Of British Columbia |
Nucleic acid-containing lipid particles and related methods
|
|
ME03091B
(me)
|
2009-12-01 |
2019-01-20 |
Translate Bio Inc |
Isporuka irnk za povećanje ekspresije proteina i enzima u humanim genetskim oboljenjima
|
|
JP5860409B2
(ja)
|
2010-01-19 |
2016-02-16 |
ポリピッド リミテッド |
徐放性核酸マトリックス組成物
|
|
AU2011237630B2
(en)
|
2010-04-06 |
2016-01-21 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of CD274/PD-L1 gene
|
|
US20130037977A1
(en)
|
2010-04-08 |
2013-02-14 |
Paul A. Burke |
Preparation of Lipid Nanoparticles
|
|
WO2011139911A2
(en)
*
|
2010-04-29 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Lipid formulated single stranded rna
|
|
WO2011141704A1
(en)
|
2010-05-12 |
2011-11-17 |
Protiva Biotherapeutics, Inc |
Novel cyclic cationic lipids and methods of use
|
|
EP2569276B1
(en)
|
2010-05-12 |
2021-02-24 |
Arbutus Biopharma Corporation |
Novel cationic lipids and methods of use thereof
|
|
US8865675B2
(en)
|
2010-05-12 |
2014-10-21 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing apolipoprotein B
|
|
JP2013531634A
(ja)
|
2010-05-24 |
2013-08-08 |
メルク・シャープ・エンド・ドーム・コーポレイション |
オリゴヌクレオチド送達のための新規なアミノアルコールカチオン性脂質
|
|
AU2011261434B2
(en)
|
2010-06-02 |
2015-11-26 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods directed to treating liver fibrosis
|
|
US9006417B2
(en)
|
2010-06-30 |
2015-04-14 |
Protiva Biotherapeutics, Inc. |
Non-liposomal systems for nucleic acid delivery
|
|
NZ606591A
(en)
*
|
2010-07-06 |
2015-02-27 |
Novartis Ag |
Cationic oil-in-water emulsions
|
|
RS54489B1
(sr)
|
2010-07-06 |
2016-06-30 |
Glaxosmithkline Biologicals Sa |
Lipozomi sa lipidima koji imaju poboljšanu pka vrednost za oslobađanje rnk
|
|
HUE047796T2
(hu)
|
2010-07-06 |
2020-05-28 |
Glaxosmithkline Biologicals Sa |
RNS bevitele több immunútvonal bekapcsolására
|
|
JP5940064B2
(ja)
|
2010-07-06 |
2016-06-29 |
ノバルティス アーゲー |
低用量のrnaを用いた大型哺乳動物の免疫化
|
|
DK2590676T3
(en)
|
2010-07-06 |
2016-10-24 |
Glaxosmithkline Biologicals Sa |
Virionlignende feed particles to self-replicating RNA molecules
|
|
US8822663B2
(en)
|
2010-08-06 |
2014-09-02 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
JP2013537423A
(ja)
|
2010-08-17 |
2013-10-03 |
メルク・シャープ・エンド・ドーム・コーポレイション |
低分子干渉核酸(siNA)を用いたB型肝炎ウイルス(HBV)遺伝子発現のRNA干渉媒介性阻害
|
|
WO2012027467A1
(en)
|
2010-08-26 |
2012-03-01 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
SMT202200311T1
(it)
|
2010-08-31 |
2022-09-14 |
Glaxosmithkline Biologicals Sa |
Liposomi pegilati per somministrare rna codificante un immunogene
|
|
EP2611927B1
(en)
|
2010-08-31 |
2018-08-01 |
Sirna Therapeutics, Inc. |
Novel single chemical entities and methods for delivery of oligonucleotides
|
|
HRP20221048T1
(hr)
|
2010-08-31 |
2022-11-11 |
Glaxosmithkline Biologicals Sa |
Mali liposomi za isporuku rna koja kodira imunogen
|
|
KR101223483B1
(ko)
*
|
2010-09-10 |
2013-01-17 |
한국과학기술연구원 |
전하결합 및 생분해성 공유결합으로 동시에 연결된 고분자―siRNA 나노입자 전달체
|
|
WO2012040184A2
(en)
|
2010-09-20 |
2012-03-29 |
Merck Sharp & Dohme Corp. |
Novel low molecular weight cationic lipids for oligonucleotide delivery
|
|
CA2811430A1
(en)
|
2010-09-30 |
2012-04-05 |
Merck Sharp & Dohme Corp. |
Low molecular weight cationic lipids for oligonucleotide delivery
|
|
DK4108671T3
(da)
|
2010-10-01 |
2025-01-06 |
Modernatx Inc |
Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf
|
|
EP3520813B1
(en)
|
2010-10-11 |
2023-04-19 |
GlaxoSmithKline Biologicals S.A. |
Antigen delivery platforms
|
|
EP3485913A1
(en)
|
2010-10-21 |
2019-05-22 |
Sirna Therapeutics, Inc. |
Low molecular weight cationic lipids for oligonucleotide delivery
|
|
DK2632472T3
(en)
|
2010-10-29 |
2018-03-19 |
Sirna Therapeutics Inc |
RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
|
|
EP2635265B1
(en)
|
2010-11-05 |
2018-04-04 |
Sirna Therapeutics, Inc. |
Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
|
|
US8853377B2
(en)
|
2010-11-30 |
2014-10-07 |
Shire Human Genetic Therapies, Inc. |
mRNA for use in treatment of human genetic diseases
|
|
US9127275B2
(en)
|
2010-12-10 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
|
|
EP2649182A4
(en)
|
2010-12-10 |
2015-05-06 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for increasing erythropoietin (epo) production
|
|
EP2691121A4
(en)
|
2011-03-29 |
2015-08-26 |
Alnylam Pharmaceuticals Inc |
COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TMPRSS6 GENE
|
|
JP2014511687A
(ja)
*
|
2011-03-31 |
2014-05-19 |
モデルナ セラピューティクス インコーポレイテッド |
工学操作された核酸の送達および製剤
|
|
US20120301537A1
(en)
*
|
2011-05-23 |
2012-11-29 |
Delta-Fly Pharma, Inc. |
LIPOSOME CONTAINING shRNA MOLECULE TARGETING A THYMIDYLATE SYNTHASE AND USE THEREOF
|
|
US8592572B2
(en)
*
|
2011-05-23 |
2013-11-26 |
Delta-Fly Pharma, Inc. |
Liposome containing shRNA molecule targeting a thymidylate synthase and use thereof
|
|
US9011903B2
(en)
|
2011-06-08 |
2015-04-21 |
Nitto Denko Corporation |
Cationic lipids for therapeutic agent delivery formulations
|
|
US10196637B2
(en)
|
2011-06-08 |
2019-02-05 |
Nitto Denko Corporation |
Retinoid-lipid drug carrier
|
|
PT2717893T
(pt)
|
2011-06-08 |
2019-08-20 |
Translate Bio Inc |
Composições de nanopartículas lipídicas e métodos para transferência de arnm
|
|
EP3564393A1
(en)
|
2011-06-21 |
2019-11-06 |
Alnylam Pharmaceuticals, Inc. |
Assays and methods for determining activity of a therapeutic agent in a subject
|
|
CN103890000B
(zh)
|
2011-06-21 |
2017-09-01 |
阿尔尼拉姆医药品有限公司 |
血管生成素样3(ANGPTL3)iRNA组合物及其使用方法
|
|
WO2012177949A2
(en)
|
2011-06-21 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibition of expression of protein c (proc) genes
|
|
KR20260004562A
(ko)
|
2011-06-21 |
2026-01-08 |
알닐람 파마슈티칼스 인코포레이티드 |
아포리포단백질 c-iii(apoc3) 유전자의 발현 억제를 위한 조성물 및 방법
|
|
EP2723390B1
(en)
|
2011-06-23 |
2017-12-27 |
Alnylam Pharmaceuticals, Inc. |
Serpina1 sirnas: compositions of matter and methods of treatment
|
|
EP3854413A1
(en)
|
2011-07-06 |
2021-07-28 |
GlaxoSmithKline Biologicals SA |
Immunogenic combination compositions and uses thereof
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
JP6113737B2
(ja)
|
2011-10-03 |
2017-04-12 |
モデルナティエックス インコーポレイテッドModernaTX,Inc. |
修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
|
|
US8999950B2
(en)
*
|
2011-10-05 |
2015-04-07 |
Protiva Biotherapeutics Inc. |
Compositions and methods for silencing aldehyde dehydrogenase
|
|
EP3069785A1
(en)
|
2011-10-25 |
2016-09-21 |
The University Of British Columbia |
Limit size lipid nanoparticles and related methods
|
|
US9320814B2
(en)
*
|
2011-11-01 |
2016-04-26 |
Board Of Regents Of The University Of Nebraska |
Polyplexes of hydrophobically-modified siRNA for delivery of siRNA
|
|
WO2013075035A1
(en)
|
2011-11-18 |
2013-05-23 |
Alnylam Pharmaceuticals |
Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases
|
|
US20140308304A1
(en)
|
2011-12-07 |
2014-10-16 |
Alnylam Pharmaceuticals, Inc. |
Lipids for the delivery of active agents
|
|
EP3988537A1
(en)
|
2011-12-07 |
2022-04-27 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
|
KR20140102759A
(ko)
|
2011-12-16 |
2014-08-22 |
모더나 세라퓨틱스, 인코포레이티드 |
변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
|
|
US9035039B2
(en)
|
2011-12-22 |
2015-05-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing SMAD4
|
|
NZ700075A
(en)
|
2012-02-24 |
2016-05-27 |
Protiva Biotherapeutics Inc |
Trialkyl cationic lipids and methods of use thereof
|
|
HK1206645A1
(en)
|
2012-03-29 |
2016-01-15 |
Shire Human Genetic Therapies, Inc. |
Ionizable cationic lipids
|
|
HK1206612A1
(en)
*
|
2012-04-02 |
2016-01-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of secreted proteins
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
EP2834259A4
(en)
|
2012-04-02 |
2016-08-24 |
Moderna Therapeutics Inc |
MODIFIED POLYNUCLEOTIDES
|
|
US10501513B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides for the production of oncology-related proteins and peptides
|
|
US9133461B2
(en)
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
|
CA2870941C
(en)
|
2012-04-19 |
2021-05-25 |
Sirna Therapeutics, Inc. |
Diester and triester based low molecular weight, biodegradable cationic lipids for oligonucleotide delivery
|
|
US9127274B2
(en)
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
|
US20150267192A1
(en)
|
2012-06-08 |
2015-09-24 |
Shire Human Genetic Therapies, Inc. |
Nuclease resistant polynucleotides and uses thereof
|
|
BR112014030677A2
(pt)
|
2012-06-08 |
2022-07-19 |
Shire Human Genetic Therapies |
distribuição pulmonar de mrna para células-alvo não-pulmonares
|
|
US9415109B2
(en)
|
2012-07-06 |
2016-08-16 |
Alnylam Pharmaceuticals, Inc. |
Stable non-aggregating nucleic acid lipid particle formulations
|
|
CN102719437A
(zh)
*
|
2012-07-11 |
2012-10-10 |
潍坊医学院 |
利用慢病毒载体介导PLK1 RNAi在治疗食管鳞癌转移中的应用
|
|
WO2014028429A2
(en)
|
2012-08-14 |
2014-02-20 |
Moderna Therapeutics, Inc. |
Enzymes and polymerases for the synthesis of rna
|
|
US9597380B2
(en)
|
2012-11-26 |
2017-03-21 |
Modernatx, Inc. |
Terminally modified RNA
|
|
PT2929031T
(pt)
|
2012-12-05 |
2018-01-19 |
Alnylam Pharmaceuticals Inc |
Composições de irna de pcsk9 e métodos de seu uso
|
|
WO2014093622A2
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
|
|
WO2014160243A1
(en)
|
2013-03-14 |
2014-10-02 |
The Trustees Of The University Of Pennsylvania |
Purification and purity assessment of rna molecules synthesized with modified nucleosides
|
|
CN114015692B
(zh)
|
2013-03-14 |
2024-12-31 |
阿尔尼拉姆医药品有限公司 |
补体组分C5 iRNA组合物及其使用方法
|
|
KR20150128687A
(ko)
|
2013-03-14 |
2015-11-18 |
샤이어 휴먼 지네틱 테라피즈 인크. |
메신저 rna의 정제 방법
|
|
CA2904151C
(en)
|
2013-03-14 |
2023-09-12 |
Shire Human Genetic Therapies, Inc. |
Cftr mrna compositions and related methods and uses
|
|
HUE055044T2
(hu)
|
2013-03-14 |
2021-10-28 |
Translate Bio Inc |
MRNS-kódolt ellenanyagok bejuttatására szolgáló eljárások és készítmények
|
|
US10258698B2
(en)
|
2013-03-14 |
2019-04-16 |
Modernatx, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
CN105143456A
(zh)
|
2013-03-15 |
2015-12-09 |
不列颠哥伦比亚大学 |
用于转染的脂质纳米粒子和相关方法
|
|
ES3032013T3
(en)
|
2013-03-15 |
2025-07-14 |
Translate Bio Inc |
Synergistic enhancement of the delivery of nucleic acids via blended formulations
|
|
US11377470B2
(en)
|
2013-03-15 |
2022-07-05 |
Modernatx, Inc. |
Ribonucleic acid purification
|
|
WO2014140856A2
(en)
|
2013-03-15 |
2014-09-18 |
Graham Lord |
Mir-142 and antagonists thereof for treating disease
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
EP3578663A1
(en)
|
2013-03-15 |
2019-12-11 |
ModernaTX, Inc. |
Manufacturing methods for production of rna transcripts
|
|
WO2014152030A1
(en)
|
2013-03-15 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Removal of dna fragments in mrna production process
|
|
WO2014144767A1
(en)
|
2013-03-15 |
2014-09-18 |
Moderna Therapeutics, Inc. |
Ion exchange purification of mrna
|
|
EP3412774A1
(en)
|
2013-05-22 |
2018-12-12 |
Alnylam Pharmaceuticals, Inc. |
Serpina1 irna compositions and methods of use thereof
|
|
TWI727917B
(zh)
|
2013-05-22 |
2021-05-21 |
美商阿尼拉製藥公司 |
TMPRSS6iRNA 組成物及其使用方法
|
|
KR20240172759A
(ko)
|
2013-06-17 |
2024-12-10 |
더 브로드 인스티튜트, 인코퍼레이티드 |
간의 표적화 및 치료를 위한 CRISPRCas 시스템, 벡터 및 조성물의 전달 및 용도
|
|
SG11201510327TA
(en)
|
2013-06-17 |
2016-01-28 |
Broad Inst Inc |
Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells
|
|
EP3597755A1
(en)
|
2013-06-17 |
2020-01-22 |
The Broad Institute, Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components
|
|
DK3019619T3
(da)
|
2013-07-11 |
2021-10-11 |
Modernatx Inc |
Sammensætninger, der omfatter syntetiske polynukleotider, som koder for crispr-beslægtede proteiner, og syntetiske sgrna'er, og anvendelsesfremgangsmåder
|
|
WO2015011633A1
(en)
|
2013-07-23 |
2015-01-29 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for delivering messenger rna
|
|
EP3041938A1
(en)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
AU2014315287A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
TWI669393B
(zh)
|
2013-10-02 |
2019-08-21 |
艾爾妮蘭製藥公司 |
抑制lect2基因表現之組合物及方法
|
|
EP3052511A4
(en)
|
2013-10-02 |
2017-05-31 |
Moderna Therapeutics, Inc. |
Polynucleotide molecules and uses thereof
|
|
EP3052521A1
(en)
|
2013-10-03 |
2016-08-10 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
|
BR122020001264B1
(pt)
|
2013-10-04 |
2022-11-22 |
Icahn School Of Medicine At Mount Sinai |
Ácido ribonucleico de fita dupla (dsrna) para inibição da expressão de alas1, composição farmacêutica para inibição da expressão de um gene alas1, métodos de inibição da expressão de alas1 em uma célula e para diminuir um nível de uma porfirina ou de um precursor de porfirina em uma célula, usos de um dsrna, método para avaliar o nível de mrna de alas1 extracelular em circulação em um indivíduo, composição e uso da mesma
|
|
WO2015061467A1
(en)
|
2013-10-22 |
2015-04-30 |
Shire Human Genetic Therapies, Inc. |
Lipid formulations for delivery of messenger rna
|
|
BR112016009014B1
(pt)
|
2013-10-22 |
2024-02-06 |
Translate Bio, Inc |
USO DE COMPOSIÇÃO COMPREENDENDO mRNA PARA DEFICIÊNCIA DE ARGININOSSUCINATO SINTETASE
|
|
EA201992208A1
(ru)
|
2013-10-22 |
2020-07-31 |
Транслейт Био, Инк. |
ЛЕЧЕНИЕ ФЕНИЛКЕТОНУРИИ С ПРИМЕНЕНИЕМ мРНК
|
|
CN105658800A
(zh)
|
2013-10-22 |
2016-06-08 |
夏尔人类遗传性治疗公司 |
Mrna的cns递送及其用途
|
|
KR102507624B1
(ko)
|
2013-11-22 |
2023-03-09 |
미나 테라퓨틱스 리미티드 |
C/ebp 알파 짧은 활성화 rna 조성물 및 사용 방법
|
|
IL314045A
(en)
|
2013-12-12 |
2024-09-01 |
Alnylam Pharmaceuticals Inc |
Complement component irna compositions and methods of use thereof
|
|
CN105899658B
(zh)
|
2013-12-12 |
2020-02-18 |
布罗德研究所有限公司 |
针对hbv和病毒性疾病以及障碍的crispr-cas系统和组合物的递送、用途和治疗应用
|
|
WO2015089354A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
|
|
EP3080271B1
(en)
|
2013-12-12 |
2020-02-12 |
The Broad Institute, Inc. |
Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
|
|
JP2017501149A
(ja)
|
2013-12-12 |
2017-01-12 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
粒子送達構成成分を用いた障害及び疾患の標的化のためのcrispr−cas系及び組成物の送達、使用及び治療適用
|
|
EP3080259B1
(en)
|
2013-12-12 |
2023-02-01 |
The Broad Institute, Inc. |
Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
|
|
EP3653229A1
(en)
|
2013-12-12 |
2020-05-20 |
The Broad Institute, Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for genome editing
|
|
KR102592370B1
(ko)
|
2014-02-11 |
2023-10-25 |
알닐람 파마슈티칼스 인코포레이티드 |
케토헥소키나제(KHK) iRNA 조성물 및 그의 사용 방법
|
|
EP3556353A3
(en)
|
2014-02-25 |
2020-03-18 |
Merck Sharp & Dohme Corp. |
Lipid nanoparticle vaccine adjuvants and antigen delivery systems
|
|
RU2021109685A
(ru)
*
|
2014-04-23 |
2021-04-13 |
МОДЕРНАТиЭкс, ИНК. |
Вакцины на основе нуклеиновых кислот
|
|
KR102739894B1
(ko)
|
2014-04-25 |
2024-12-05 |
샤이어 휴먼 지네틱 테라피즈 인크. |
메신저 rna 의 정제 방법
|
|
MX382901B
(es)
|
2014-05-22 |
2025-03-13 |
Alnylam Pharmaceuticals Inc |
Composiciones de angiotensinogeno (agt) arni y métodos de uso de las mismas.
|
|
US10022455B2
(en)
|
2014-05-30 |
2018-07-17 |
Translate Bio, Inc. |
Biodegradable lipids for delivery of nucleic acids
|
|
JP6779866B2
(ja)
|
2014-06-13 |
2020-11-04 |
チルドレンズ メディカル センター コーポレイション |
ミトコンドリアを単離するための製品および方法
|
|
US10286086B2
(en)
|
2014-06-19 |
2019-05-14 |
Modernatx, Inc. |
Alternative nucleic acid molecules and uses thereof
|
|
AU2015279968B2
(en)
|
2014-06-24 |
2019-11-14 |
Translate Bio, Inc. |
Stereochemically enriched compositions for delivery of nucleic acids
|
|
IL289934B2
(en)
|
2014-06-25 |
2023-04-01 |
Acuitas Therapeutics Inc |
Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
CN106456547B
(zh)
|
2014-07-02 |
2021-11-12 |
川斯勒佰尔公司 |
信使rna的包封
|
|
EP3169693B1
(en)
|
2014-07-16 |
2022-03-09 |
ModernaTX, Inc. |
Chimeric polynucleotides
|
|
US10407683B2
(en)
|
2014-07-16 |
2019-09-10 |
Modernatx, Inc. |
Circular polynucleotides
|
|
WO2016010840A1
(en)
*
|
2014-07-16 |
2016-01-21 |
Novartis Ag |
Method of encapsulating a nucleic acid in a lipid nanoparticle host
|
|
EP3171895A1
(en)
|
2014-07-23 |
2017-05-31 |
Modernatx, Inc. |
Modified polynucleotides for the production of intrabodies
|
|
EP3686279B1
(en)
|
2014-08-17 |
2023-01-04 |
The Broad Institute, Inc. |
Genome editing using cas9 nickases
|
|
US9765333B2
(en)
|
2014-08-21 |
2017-09-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing marburg virus gene expression
|
|
LT3185957T
(lt)
*
|
2014-08-29 |
2022-09-26 |
Alnylam Pharmaceuticals, Inc. |
Patisiranas, skirtas naudoti transtiretino amiloidozei gydyti
|
|
WO2016040589A1
(en)
|
2014-09-12 |
2016-03-17 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting complement component c5 and methods of use thereof
|
|
WO2016049163A2
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
|
|
WO2016049258A2
(en)
|
2014-09-25 |
2016-03-31 |
The Broad Institute Inc. |
Functional screening with optimized functional crispr-cas systems
|
|
CR20170174A
(es)
|
2014-10-02 |
2017-11-07 |
Protiva Biotherapeutics Inc |
Composiciones y métodos para el silenciamiento de la expresión cénica del virus de la hepatitis b
|
|
TWI755351B
(zh)
|
2014-10-10 |
2022-02-21 |
美商艾爾妮蘭製藥公司 |
用於抑制hao1(羥酸氧化酶1(乙醇酸鹽氧化酶))基因表現的組合物及方法
|
|
EP3207138B1
(en)
|
2014-10-17 |
2020-07-15 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
|
|
WO2016069694A2
(en)
|
2014-10-30 |
2016-05-06 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
|
|
JOP20200092A1
(ar)
|
2014-11-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
|
|
CN107250362B
(zh)
|
2014-11-17 |
2021-10-22 |
阿尔尼拉姆医药品有限公司 |
载脂蛋白C3(APOC3)iRNA组合物及其使用方法
|
|
WO2016090262A1
(en)
|
2014-12-05 |
2016-06-09 |
Shire Human Genetic Therapies, Inc. |
Messenger rna therapy for treatment of articular disease
|
|
WO2016094880A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
|
|
EP3230452B1
(en)
|
2014-12-12 |
2025-06-11 |
The Broad Institute, Inc. |
Dead guides for crispr transcription factors
|
|
WO2016094874A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Escorted and functionalized guides for crispr-cas systems
|
|
EP3889260A1
(en)
|
2014-12-12 |
2021-10-06 |
The Broad Institute, Inc. |
Protected guide rnas (pgrnas)
|
|
US20170369872A1
(en)
|
2014-12-18 |
2017-12-28 |
Alnylam Pharmaceuticals, Inc. |
Reversir tm compounds
|
|
WO2016100974A1
(en)
|
2014-12-19 |
2016-06-23 |
The Broad Institute Inc. |
Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing
|
|
WO2016106236A1
(en)
|
2014-12-23 |
2016-06-30 |
The Broad Institute Inc. |
Rna-targeting system
|
|
CA2970370A1
(en)
|
2014-12-24 |
2016-06-30 |
Massachusetts Institute Of Technology |
Crispr having or associated with destabilization domains
|
|
JP2018509387A
(ja)
|
2015-01-21 |
2018-04-05 |
フェーズアールエックス インコーポレイテッド |
細胞に治療および診断剤を送達するための方法、組成物、ならびにシステム
|
|
JP2018510621A
(ja)
|
2015-02-13 |
2018-04-19 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
パタチン様ホスホリパーゼドメイン含有3(PNPLA3)iRNA組成物およびその使用方法
|
|
US10172924B2
(en)
|
2015-03-19 |
2019-01-08 |
Translate Bio, Inc. |
MRNA therapy for pompe disease
|
|
WO2016164746A1
(en)
|
2015-04-08 |
2016-10-13 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
|
EP4353257A3
(en)
|
2015-04-13 |
2024-08-07 |
CureVac Manufacturing GmbH |
Method for producing rna compositions
|
|
CN104997801A
(zh)
*
|
2015-05-28 |
2015-10-28 |
厦门成坤生物技术有限公司 |
包含季铵盐类化合物和siRNA的组合物及其制备方法
|
|
US20180245074A1
(en)
|
2015-06-04 |
2018-08-30 |
Protiva Biotherapeutics, Inc. |
Treating hepatitis b virus infection using crispr
|
|
WO2016201301A1
(en)
|
2015-06-12 |
2016-12-15 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions and methods of use thereof
|
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
|
WO2016205749A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
|
WO2016205745A2
(en)
*
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Cell sorting
|
|
MX392008B
(es)
|
2015-06-18 |
2025-03-21 |
Broad Inst Inc |
Mutaciones de la enzima crispr que reducen los efectos fuera del blanco
|
|
EP4159856A1
(en)
|
2015-06-18 |
2023-04-05 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
|
WO2016205323A1
(en)
|
2015-06-18 |
2016-12-22 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
|
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
|
CN114085198A
(zh)
|
2015-06-29 |
2022-02-25 |
爱康泰生治疗公司 |
用于递送核酸的脂质和脂质纳米颗粒制剂
|
|
DK3319980T3
(da)
*
|
2015-07-10 |
2021-11-22 |
Peptinovo Biopharma Inc |
Formuleringer til forbedring af virkningen af hydrofobe lægemidler
|
|
WO2017011286A1
(en)
|
2015-07-10 |
2017-01-19 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof
|
|
US11364292B2
(en)
|
2015-07-21 |
2022-06-21 |
Modernatx, Inc. |
CHIKV RNA vaccines
|
|
EP4218805A1
(en)
|
2015-07-21 |
2023-08-02 |
ModernaTX, Inc. |
Infectious disease vaccines
|
|
EP3329003A2
(en)
|
2015-07-29 |
2018-06-06 |
Arbutus Biopharma Corporation |
Compositions and methods for silencing hepatitis b virus gene expression
|
|
EP3328394A4
(en)
|
2015-07-30 |
2019-03-13 |
ModernaTX, Inc. |
CONCATEMEE peptide epitope RNAs
|
|
PL3329002T3
(pl)
|
2015-07-31 |
2021-04-19 |
Alnylam Pharmaceuticals, Inc. |
Kompozycje irna transtyretyny (ttr) i sposoby ich zastosowania do leczenia lub zapobiegania chorobom związanym z ttr
|
|
WO2017031232A1
(en)
|
2015-08-17 |
2017-02-23 |
Modernatx, Inc. |
Methods for preparing particles and related compositions
|
|
AU2016308339A1
(en)
|
2015-08-18 |
2018-04-12 |
Baylor College Of Medicine |
Methods and compositions for altering function and structure of chromatin loops and/or domains
|
|
EP3340967B1
(en)
|
2015-08-24 |
2024-05-22 |
Halo-Bio Rnai Therapeutics, Inc. |
Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
|
|
SG10202007937SA
(en)
|
2015-09-02 |
2020-09-29 |
Alnylam Pharmaceuticals Inc |
PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
WO2017048620A1
(en)
|
2015-09-14 |
2017-03-23 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof
|
|
WO2017049286A1
(en)
|
2015-09-17 |
2017-03-23 |
Moderna Therapeutics, Inc. |
Polynucleotides containing a morpholino linker
|
|
PL3350333T3
(pl)
|
2015-09-17 |
2022-03-07 |
Modernatx, Inc. |
Polinukleotydy zawierające region stabilizujący ogon
|
|
EP3350157B1
(en)
|
2015-09-17 |
2022-01-05 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
AU2016336344A1
(en)
|
2015-10-05 |
2018-04-19 |
Modernatx, Inc. |
Methods for therapeutic administration of messenger ribonucleic acid drugs
|
|
WO2017069958A2
(en)
|
2015-10-09 |
2017-04-27 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
|
ES2862412T3
(es)
|
2015-10-14 |
2021-10-07 |
Translate Bio Inc |
Modificación de enzimas relacionados con el ARN para producción mejorada
|
|
MX382522B
(es)
|
2015-10-16 |
2025-03-13 |
Ipsen Biopharm Ltd |
Composiciones farmaceuticas estabilizantes de camptotecina.
|
|
CA3002819A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Sexually transmitted disease vaccines
|
|
JP6925688B2
(ja)
|
2015-10-22 |
2021-08-25 |
モデルナティーエックス, インコーポレイテッド |
水痘帯状疱疹ウイルス(vzv)のための核酸ワクチン
|
|
EP3364950A4
(en)
|
2015-10-22 |
2019-10-23 |
ModernaTX, Inc. |
VACCINES AGAINST TROPICAL DISEASES
|
|
CA3002922A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
WO2017070605A1
(en)
|
2015-10-22 |
2017-04-27 |
The Broad Institute Inc. |
Type vi-b crispr enzymes and systems
|
|
WO2017074788A1
(en)
|
2015-10-27 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for targeting cancer-specific sequence variations
|
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
|
WO2017075478A2
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
|
|
RS63986B1
(sr)
|
2015-10-28 |
2023-03-31 |
Acuitas Therapeutics Inc |
Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina
|
|
WO2017095946A1
(en)
|
2015-11-30 |
2017-06-08 |
Flagship Pioneering, Inc. |
Methods and compositions relating to chondrisomes
|
|
ES2924407T3
(es)
|
2015-12-10 |
2022-10-06 |
Modernatx Inc |
Composiciones y procedimientos para el suministro de agentes terapéuticos
|
|
US12110490B2
(en)
|
2015-12-18 |
2024-10-08 |
The Broad Institute, Inc. |
CRISPR enzymes and systems
|
|
SI3394030T1
(sl)
|
2015-12-22 |
2022-04-29 |
Modernatx, Inc. |
Sestave za doziranje sredstev v celice
|
|
LT3394093T
(lt)
|
2015-12-23 |
2022-04-25 |
Modernatx, Inc. |
Ox40 ligandus koduojančių polinukleotidų naudojimo būdai
|
|
EP3400023A1
(en)
|
2016-01-10 |
2018-11-14 |
ModernaTX, Inc. |
Therapeutic mrnas encoding anti ctla-4 antibodies
|
|
FI4272834T3
(fi)
|
2016-01-15 |
2025-12-05 |
Childrens Medical Ct Corp |
Mitokondrioiden ja yhdistettyjen mitokondriaalisten aineiden terapeuttinen käyttö
|
|
CN109072223B
(zh)
|
2016-04-08 |
2022-10-21 |
川斯勒佰尔公司 |
多聚体编码核酸及其用途
|
|
MA45295A
(fr)
|
2016-04-19 |
2019-02-27 |
Alnylam Pharmaceuticals Inc |
Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
|
|
KR20260004568A
(ko)
|
2016-04-19 |
2026-01-08 |
더 브로드 인스티튜트, 인코퍼레이티드 |
신규한 crispr 효소 및 시스템
|
|
EP3445853A1
(en)
|
2016-04-19 |
2019-02-27 |
The Broad Institute, Inc. |
Cpf1 complexes with reduced indel activity
|
|
WO2017189308A1
(en)
|
2016-04-19 |
2017-11-02 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
|
MA45052A
(fr)
|
2016-05-18 |
2019-03-27 |
Modernatx Inc |
Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille
|
|
EP3458083B1
(en)
|
2016-05-18 |
2022-11-02 |
ModernaTX, Inc. |
Polynucleotides encoding interleukin-12 (il12) and uses thereof
|
|
KR102533456B1
(ko)
|
2016-05-18 |
2023-05-17 |
모더나티엑스, 인크. |
릴랙신을 인코딩하는 폴리뉴클레오타이드
|
|
HRP20221135T8
(hr)
*
|
2016-05-18 |
2023-02-03 |
Modernatx, Inc. |
KOMBINACIJE mRNK KOJE KODIRAJU IMUNOMODULIRAJUĆE POLIPEPTIDE I NJIHOVE UPOTREBE
|
|
EP3469083A1
(en)
|
2016-06-10 |
2019-04-17 |
Alnylam Pharmaceuticals, Inc. |
COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
|
|
EP3469074B1
(en)
|
2016-06-13 |
2020-12-09 |
Translate Bio, Inc. |
Messenger rna therapy for the treatment of ornithine transcarbamylase deficiency
|
|
US20200069599A1
(en)
*
|
2016-06-14 |
2020-03-05 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
KR20190019168A
(ko)
|
2016-06-17 |
2019-02-26 |
더 브로드 인스티튜트, 인코퍼레이티드 |
제vi형 crispr 오솔로그 및 시스템
|
|
US12385034B2
(en)
|
2016-06-24 |
2025-08-12 |
Modernatx, Inc. |
Methods and apparatus for filtration
|
|
US20210222164A1
(en)
|
2016-06-29 |
2021-07-22 |
The Broad Institute, Inc. |
Crispr-cas systems having destabilization domain
|
|
AU2017286980B2
(en)
|
2016-06-30 |
2023-10-26 |
Arbutus Biopharma Corporation |
Compositions and methods for delivering messenger RNA
|
|
WO2018009838A1
(en)
|
2016-07-07 |
2018-01-11 |
Rubius Therapeutics, Inc. |
Compositions and methods related to therapeutic cell systems expressing exogenous rna
|
|
CN110312799A
(zh)
|
2016-08-17 |
2019-10-08 |
博德研究所 |
新型crispr酶和系统
|
|
WO2018035388A1
(en)
|
2016-08-17 |
2018-02-22 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
|
EP3500295A2
(en)
|
2016-08-19 |
2019-06-26 |
CureVac AG |
Rna for cancer therapy
|
|
MA45999A
(fr)
|
2016-08-22 |
2019-06-26 |
Arbutus Biopharma Corp |
Anticorps anti-pd-1, ou leurs fragments, pour le traitement de l'hépatite b
|
|
WO2018049025A2
(en)
|
2016-09-07 |
2018-03-15 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses
|
|
WO2018064208A1
(en)
|
2016-09-28 |
2018-04-05 |
The Broad Institute, Inc. |
Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof
|
|
WO2018119514A1
(en)
*
|
2016-12-28 |
2018-07-05 |
Precision Nanosystems Inc. |
Compositions for transfecting resistant cell types
|
|
US20210284998A1
(en)
|
2016-10-03 |
2021-09-16 |
Precision Nanosystems Inc. |
Compositions for Transfecting Resistant Cell Types
|
|
WO2018067991A1
(en)
|
2016-10-07 |
2018-04-12 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
|
CA3041307A1
(en)
|
2016-10-21 |
2018-04-26 |
Giuseppe Ciaramella |
Human cytomegalovirus vaccine
|
|
EP4714454A2
(en)
|
2016-10-26 |
2026-03-25 |
Acuitas Therapeutics Inc. |
Lipid nanoparticle formulations
|
|
US12491261B2
(en)
|
2016-10-26 |
2025-12-09 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
US11583504B2
(en)
|
2016-11-08 |
2023-02-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
US10925958B2
(en)
|
2016-11-11 |
2021-02-23 |
Modernatx, Inc. |
Influenza vaccine
|
|
TW202313978A
(zh)
|
2016-11-23 |
2023-04-01 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
|
|
MA50335A
(fr)
|
2016-12-08 |
2020-08-19 |
Modernatx Inc |
Vaccins à acide nucléique contre des virus respiratoires
|
|
JP2020501545A
(ja)
|
2016-12-08 |
2020-01-23 |
キュアバック アーゲー |
肝疾患の処置または予防のためのrna
|
|
WO2018104540A1
(en)
|
2016-12-08 |
2018-06-14 |
Curevac Ag |
Rnas for wound healing
|
|
SG10201913552UA
(en)
|
2016-12-16 |
2020-03-30 |
Alnylam Pharmaceuticals Inc |
Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions
|
|
US11141476B2
(en)
|
2016-12-23 |
2021-10-12 |
Curevac Ag |
MERS coronavirus vaccine
|
|
WO2018115525A1
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Lassa virus vaccine
|
|
US11524066B2
(en)
|
2016-12-23 |
2022-12-13 |
CureVac SE |
Henipavirus vaccine
|
|
MX2019010155A
(es)
|
2017-02-27 |
2020-12-10 |
Translate Bio Inc |
Arnm de cftr optimizado por codón novedoso.
|
|
US11752206B2
(en)
*
|
2017-03-15 |
2023-09-12 |
Modernatx, Inc. |
Herpes simplex virus vaccine
|
|
CN120330163A
(zh)
|
2017-03-15 |
2025-07-18 |
博德研究所 |
新型cas13b直向同源物crispr酶和系统
|
|
WO2018170260A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Respiratory syncytial virus vaccine
|
|
WO2018170245A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
ES2911186T3
(es)
|
2017-03-15 |
2022-05-18 |
Modernatx Inc |
Formas cristalinas de aminolípidos
|
|
US11045540B2
(en)
|
2017-03-15 |
2021-06-29 |
Modernatx, Inc. |
Varicella zoster virus (VZV) vaccine
|
|
FI3596041T3
(fi)
|
2017-03-15 |
2023-01-31 |
|
Yhdiste ja koostumuksia terapeuttisten aineiden antamiseen solun sisään
|
|
JP7332478B2
(ja)
|
2017-03-15 |
2023-08-23 |
モデルナティエックス インコーポレイテッド |
脂質ナノ粒子製剤
|
|
WO2019012336A2
(en)
|
2017-03-17 |
2019-01-17 |
Newcastle University |
ADENO-ASSOCIATED VIRAL VECTOR DELIVERY OF A MICRO-DYSTROPHIN FRAGMENT FOR TREATING MUSCLE DYSTROPHY
|
|
JP2020514370A
(ja)
|
2017-03-17 |
2020-05-21 |
キュアバック アーゲー |
組合せ抗癌療法のためのrnaワクチン及び免疫チェックポイント阻害剤
|
|
EP3595676A4
(en)
|
2017-03-17 |
2021-05-05 |
Modernatx, Inc. |
RNA VACCINES AGAINST ZOONOSES
|
|
KR102842382B1
(ko)
|
2017-03-24 |
2025-08-04 |
큐어백 에스이 |
Crispr-연관 단백질을 암호화하는 핵산 및 이의 용도
|
|
EP3607074A4
(en)
|
2017-04-05 |
2021-07-07 |
Modernatx, Inc. |
REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY
|
|
CA3059757A1
(en)
|
2017-04-12 |
2018-10-18 |
Massachusetts Institute Of Technology |
Novel type vi crispr orthologs and systems
|
|
WO2018191719A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipid delivery of therapeutic agents to adipose tissue
|
|
WO2018191657A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
|
WO2018191750A2
(en)
|
2017-04-14 |
2018-10-18 |
The Broad Institute Inc. |
Novel delivery of large payloads
|
|
CN118384268A
(zh)
|
2017-04-18 |
2024-07-26 |
阿尔尼拉姆医药品有限公司 |
具有乙肝病毒(hbv)感染的受试者的治疗方法
|
|
WO2018200943A1
(en)
|
2017-04-28 |
2018-11-01 |
Acuitas Therapeutics, Inc. |
Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
US11591601B2
(en)
|
2017-05-05 |
2023-02-28 |
The Broad Institute, Inc. |
Methods for identification and modification of lncRNA associated with target genotypes and phenotypes
|
|
KR20250021608A
(ko)
|
2017-05-08 |
2025-02-13 |
플래그쉽 파이어니어링 이노베이션스 브이, 인크. |
막 융합을 촉진시키기 위한 조성물 및 그의 용도
|
|
WO2018213476A1
(en)
|
2017-05-16 |
2018-11-22 |
Translate Bio, Inc. |
Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
|
|
WO2018213726A1
(en)
|
2017-05-18 |
2018-11-22 |
The Broad Institute, Inc. |
Systems, methods, and compositions for targeted nucleic acid editing
|
|
AR112706A1
(es)
|
2017-05-31 |
2019-12-04 |
Ultragenyx Pharmaceutical Inc |
Productos terapéuticos para la glucogenosis tipo iii
|
|
US11939600B2
(en)
|
2017-05-31 |
2024-03-26 |
Arcturus Therapeutics, Inc. |
Compositions and methods for treating phenylketonuria
|
|
WO2018222890A1
(en)
|
2017-05-31 |
2018-12-06 |
Arcturus Therapeutics, Inc. |
Synthesis and structure of high potency rna therapeutics
|
|
AU2018285860A1
(en)
|
2017-06-13 |
2020-01-02 |
Flagship Pioneering Innovations V, Inc. |
Compositions comprising curons and uses thereof
|
|
EP3638678B1
(en)
|
2017-06-14 |
2025-12-03 |
ModernaTX, Inc. |
Compounds and compositions for intracellular delivery of agents
|
|
US11786607B2
(en)
|
2017-06-15 |
2023-10-17 |
Modernatx, Inc. |
RNA formulations
|
|
BR112019028280A2
(pt)
|
2017-07-04 |
2020-07-14 |
Curevac Ag |
moléculas de ácido nucleico
|
|
JP7277432B2
(ja)
|
2017-07-13 |
2023-05-19 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
乳酸脱水素酵素A(LDHA)iRNA組成物及びその使用方法
|
|
WO2019036008A1
(en)
|
2017-08-16 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
|
|
JP7461872B2
(ja)
|
2017-08-17 |
2024-04-04 |
アクイタス セラピューティクス インコーポレイテッド |
脂質ナノ粒子製剤における使用のための脂質
|
|
WO2019036030A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
|
|
WO2019036028A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
|
|
US20190062788A1
(en)
|
2017-08-22 |
2019-02-28 |
Rubius Therapeutics, Inc. |
Lipid nanoparticle methods and compositions for producing engineered erythroid cells
|
|
EP3673069A1
(en)
|
2017-08-22 |
2020-07-01 |
CureVac AG |
Bunyavirales vaccine
|
|
AU2018326799A1
(en)
|
2017-08-31 |
2020-02-27 |
Modernatx, Inc. |
Methods of making lipid nanoparticles
|
|
EP4183882A1
(en)
|
2017-09-08 |
2023-05-24 |
MiNA Therapeutics Limited |
Stabilized hnf4a sarna compositions and methods of use
|
|
EP4219715A3
(en)
|
2017-09-08 |
2023-09-06 |
MiNA Therapeutics Limited |
Stabilized cebpa sarna compositions and methods of use
|
|
MA50253A
(fr)
|
2017-09-14 |
2020-07-22 |
Modernatx Inc |
Vaccins à arn contre le virus zika
|
|
BR112020005230A2
(pt)
|
2017-09-19 |
2020-09-24 |
Alnylam Pharmaceuticals, Inc. |
composições e métodos para o tratamento da amiloidose mediada por transtiretina (ttr)
|
|
KR20200066616A
(ko)
|
2017-09-21 |
2020-06-10 |
더 브로드 인스티튜트, 인코퍼레이티드 |
표적화된 핵산 편집을 위한 시스템, 방법 및 조성물
|
|
WO2019071054A1
(en)
|
2017-10-04 |
2019-04-11 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR MODIFYING THE FUNCTION AND STRUCTURE OF BUCKLES AND / OR CHROMATIN DOMAINS
|
|
US20220233568A1
(en)
|
2017-10-19 |
2022-07-28 |
Curevac Ag |
Novel artificial nucleic acid molecules
|
|
US12227742B2
(en)
|
2017-10-23 |
2025-02-18 |
The Broad Institute, Inc. |
Nucleic acid modifiers
|
|
US11547614B2
(en)
|
2017-10-31 |
2023-01-10 |
The Broad Institute, Inc. |
Methods and compositions for studying cell evolution
|
|
WO2019089828A1
(en)
|
2017-10-31 |
2019-05-09 |
Acuitas Therapeutics, Inc. |
Lamellar lipid nanoparticles
|
|
US11692002B2
(en)
|
2017-11-08 |
2023-07-04 |
CureVac SE |
RNA sequence adaptation
|
|
EP3710039A4
(en)
|
2017-11-13 |
2021-08-04 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH
|
|
US20200385719A1
(en)
|
2017-11-16 |
2020-12-10 |
Alnylam Pharmaceuticals, Inc. |
Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
|
|
WO2019100039A1
(en)
|
2017-11-20 |
2019-05-23 |
Alnylam Pharmaceuticals, Inc. |
Serum amyloid p component (apcs) irna compositions and methods of use thereof
|
|
WO2019115635A1
(en)
|
2017-12-13 |
2019-06-20 |
Curevac Ag |
Flavivirus vaccine
|
|
WO2019118806A1
(en)
|
2017-12-14 |
2019-06-20 |
Solid Biosciences Inc. |
Non-viral production and delivery of genes
|
|
BR112020012088A2
(pt)
|
2017-12-18 |
2020-11-17 |
Alnylam Pharmaceuticals, Inc. |
composições de irna do grupo de elevada mobilidade box-1 (hmgb1) e métodos de uso dos mesmos
|
|
WO2019126593A1
(en)
|
2017-12-20 |
2019-06-27 |
Translate Bio, Inc. |
Improved composition and methods for treatment of ornithine transcarbamylase deficiency
|
|
US20230193242A1
(en)
|
2017-12-22 |
2023-06-22 |
The Broad Institute, Inc. |
Cas12b systems, methods, and compositions for targeted dna base editing
|
|
CN118512596A
(zh)
*
|
2017-12-27 |
2024-08-20 |
武田药品工业株式会社 |
含核酸脂质纳米粒子及其用途
|
|
CN112218651A
(zh)
|
2018-01-08 |
2021-01-12 |
诺华公司 |
用于与嵌合抗原受体疗法组合的免疫增强rna
|
|
US20190330591A1
(en)
|
2018-01-10 |
2019-10-31 |
Rubius Therapeutics, Inc. |
Amplifiable rnas for therapeutic cell systems
|
|
WO2019148101A1
(en)
|
2018-01-29 |
2019-08-01 |
Modernatx, Inc. |
Rsv rna vaccines
|
|
WO2019166877A1
(en)
|
2018-03-02 |
2019-09-06 |
Sixfold Bioscience Ltd. |
Compositions for delivery of cargo to cells
|
|
WO2019193183A2
(en)
|
2018-04-05 |
2019-10-10 |
Curevac Ag |
Novel yellow fever nucleic acid molecules for vaccination
|
|
US11566246B2
(en)
|
2018-04-12 |
2023-01-31 |
Mina Therapeutics Limited |
SIRT1-saRNA compositions and methods of use
|
|
BR112020020670A2
(pt)
|
2018-04-12 |
2021-03-02 |
Wave Life Sciences Ltd. |
composição de oligonucleotídeo, composição farmacêutica, método para alterar o splicing de uma transcrição alvo, método para tratar distrofia muscular, método para preparar um oligonucleotídeo ou uma composição de oligonucleotídeo do mesmo e oligonucleotídeo
|
|
SG11202008225PA
(en)
|
2018-04-17 |
2020-11-27 |
Curevac Ag |
Novel rsv rna molecules and compositions for vaccination
|
|
TWI844541B
(zh)
|
2018-05-11 |
2024-06-11 |
新加坡商波濤生命科學有限公司 |
寡核苷酸組成物及其使用方法
|
|
TWI851574B
(zh)
|
2018-05-14 |
2024-08-11 |
美商阿尼拉製藥公司 |
血管收縮素原(AGT)iRNA組成物及其使用方法
|
|
PL3805198T3
(pl)
|
2018-06-08 |
2024-02-12 |
Fujifilm Corporation |
Związek, jego sól i cząstki lipidowe
|
|
EP4591888A3
(en)
|
2018-06-18 |
2026-01-21 |
Research Institute at Nationwide Children's Hospital |
Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy
|
|
US12357580B2
(en)
|
2018-06-19 |
2025-07-15 |
The Board Of Regents Of The University Of Texas System |
Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids
|
|
EP3813874A1
(en)
|
2018-06-27 |
2021-05-05 |
CureVac AG |
Novel lassa virus rna molecules and compositions for vaccination
|
|
EP3833761A1
(en)
|
2018-08-07 |
2021-06-16 |
The Broad Institute, Inc. |
Novel cas12b enzymes and systems
|
|
EP3837367A1
(en)
|
2018-08-16 |
2021-06-23 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
|
WO2020041380A1
(en)
|
2018-08-20 |
2020-02-27 |
The Broad Institute, Inc. |
Methods and compositions for optochemical control of crispr-cas9
|
|
WO2020041793A1
(en)
|
2018-08-24 |
2020-02-27 |
Translate Bio, Inc. |
Methods for purification of messenger rna
|
|
GB2592505B
(en)
|
2018-09-04 |
2023-05-03 |
Univ Texas |
Compositions and methods for organ specific delivery of nucleic acids
|
|
WO2020051220A1
(en)
|
2018-09-04 |
2020-03-12 |
The Board of the Regents of the University of Texas System |
Compositions and methods for organ specific delivery of nucleic acids
|
|
US20210332367A1
(en)
|
2018-09-18 |
2021-10-28 |
Alnylam Pharmaceuticals, Inc. |
KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
WO2020061284A1
(en)
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
Peg lipids and uses thereof
|
|
EP3853202A1
(en)
|
2018-09-19 |
2021-07-28 |
ModernaTX, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
EP4509118A3
(en)
|
2018-09-19 |
2025-05-14 |
ModernaTX, Inc. |
High-purity peg lipids and uses thereof
|
|
US12090235B2
(en)
|
2018-09-20 |
2024-09-17 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
EP4613367A1
(en)
|
2018-09-21 |
2025-09-10 |
Acuitas Therapeutics, Inc. |
Systems and methods for manufacturing lipid nanoparticles and liposomes
|
|
MX2021003421A
(es)
|
2018-09-28 |
2021-06-15 |
Nutcracker Therapeutics Inc |
Formulaciones de nanoparticulas lipidicas que comprenden compuestos peptidicos cationicos lipidados para el suministro de acidos nucleicos.
|
|
EP3860561B1
(en)
*
|
2018-10-01 |
2023-06-21 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
|
JP7555123B2
(ja)
|
2018-10-09 |
2024-09-24 |
ザ ユニヴァーシティ オブ ブリティッシュ コロンビア |
有機溶媒不含かつ劣化剤不含のトランスフェクション・コンピテント・ベシクルを含む組成物及びシステム並びにそれらに関連する方法
|
|
US10913951B2
(en)
|
2018-10-31 |
2021-02-09 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
|
|
US12357705B2
(en)
|
2018-11-09 |
2025-07-15 |
Arbutus Biopharma Corporation |
Negatively charged peg-lipid conjugates
|
|
EP3877001A4
(en)
|
2018-11-09 |
2022-08-17 |
Arbutus Biopharma Corporation |
CATIONIC LIPIDS CONTAINING SILICON
|
|
EA202191313A1
(ru)
|
2018-11-09 |
2022-01-26 |
Арбутус Биофарма Корпорэйшн |
Композиции на основе липидных наночастиц
|
|
MX2021005969A
(es)
|
2018-11-21 |
2021-09-14 |
Translate Bio Inc |
Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr nebulizado.
|
|
EP3894559A4
(en)
|
2018-12-03 |
2023-04-05 |
Triplet Therapeutics, Inc. |
METHODS OF TREATMENT OF TRINUCLEOTIDE REPEAT EXPANSION DISORDERS RELATED TO MLH3 ACTIVITY
|
|
CA3122080A1
(en)
|
2018-12-06 |
2020-06-11 |
Arcturus Therapeutics, Inc. |
Compositions and methods for treating ornithine transcarbamylase deficiency
|
|
US11166996B2
(en)
|
2018-12-12 |
2021-11-09 |
Flagship Pioneering Innovations V, Inc. |
Anellovirus compositions and methods of use
|
|
TW202039534A
(zh)
|
2018-12-14 |
2020-11-01 |
美商美國禮來大藥廠 |
KRAS變體mRNA分子
|
|
WO2020128816A2
(en)
|
2018-12-20 |
2020-06-25 |
Pfizer Inc. |
Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent
|
|
EP3898977A1
(en)
|
2018-12-20 |
2021-10-27 |
Praxis Precision Medicines, Inc. |
Compositions and methods for the treatment of kcnt1 related disorders
|
|
CA3118034A1
(en)
|
2018-12-21 |
2020-06-25 |
Curevac Ag |
Rna for malaria vaccines
|
|
US12042527B2
(en)
|
2019-01-08 |
2024-07-23 |
Modernatx, Inc. |
Use of mRNAs encoding OX40L, IL-23 and IL-36gamma in combination with immune checkpoint blockade for treating particular cancers
|
|
TWI852977B
(zh)
|
2019-01-10 |
2024-08-21 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
|
CA3125485A1
(en)
|
2019-01-11 |
2020-07-16 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
WO2020161342A1
(en)
|
2019-02-08 |
2020-08-13 |
Curevac Ag |
Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
|
|
US11351242B1
(en)
|
2019-02-12 |
2022-06-07 |
Modernatx, Inc. |
HMPV/hPIV3 mRNA vaccine composition
|
|
US12070495B2
(en)
|
2019-03-15 |
2024-08-27 |
Modernatx, Inc. |
HIV RNA vaccines
|
|
US12534714B2
(en)
|
2019-03-18 |
2026-01-27 |
The Broad Institute, Inc. |
Type VII CRISPR proteins and systems
|
|
WO2020208361A1
(en)
|
2019-04-12 |
2020-10-15 |
Mina Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
|
WO2020236972A2
(en)
|
2019-05-20 |
2020-11-26 |
The Broad Institute, Inc. |
Non-class i multi-component nucleic acid targeting systems
|
|
EP3981435B1
(en)
|
2019-06-07 |
2023-08-16 |
FUJIFILM Corporation |
Lipid composition
|
|
CN114375334B
(zh)
|
2019-06-07 |
2026-03-20 |
斯克里贝治疗公司 |
工程化CasX系统
|
|
WO2020254535A1
(en)
|
2019-06-18 |
2020-12-24 |
Curevac Ag |
Rotavirus mrna vaccine
|
|
CN114423869A
(zh)
|
2019-07-19 |
2022-04-29 |
旗舰先锋创新Vi有限责任公司 |
重组酶组合物和使用方法
|
|
US12569438B2
(en)
|
2019-07-29 |
2026-03-10 |
Georgia Tech Research Corporation |
Nanomaterials containing constrained lipids and uses thereof
|
|
JP7692829B2
(ja)
|
2019-07-30 |
2025-06-16 |
塩野義製薬株式会社 |
Murf1を標的とする核酸医薬
|
|
WO2021022108A2
(en)
|
2019-08-01 |
2021-02-04 |
Alnylam Pharmaceuticals, Inc. |
CARBOXYPEPTIDASE B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
WO2021022109A1
(en)
|
2019-08-01 |
2021-02-04 |
Alnylam Pharmaceuticals, Inc. |
SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
WO2021030522A1
(en)
|
2019-08-13 |
2021-02-18 |
Alnylam Pharmaceuticals, Inc. |
SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
|
GEP20257820B
(en)
|
2019-08-14 |
2025-11-10 |
Acuitas Therapeutics Inc |
Improved lipid nanoparticles for delivery of nucleic acids
|
|
JP2022544412A
(ja)
|
2019-08-14 |
2022-10-18 |
キュアバック アーゲー |
免疫賦活特性が減少したrna組み合わせおよび組成物
|
|
PH12022550167A1
(en)
|
2019-08-16 |
2023-05-08 |
Regeneron Pharma |
High concentration anti-c5 formulations
|
|
EP4022058A2
(en)
|
2019-08-30 |
2022-07-06 |
Sixfold Bioscience Ltd. |
Compositions for transfer of cargo to cells
|
|
MX2022002689A
(es)
|
2019-09-03 |
2022-04-07 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para inhibir la expresion del gen de quimiotaxina derivada de celulas de leucocitos 2 (lect2).
|
|
JP7700101B2
(ja)
|
2019-09-06 |
2025-06-30 |
ジェネレーション バイオ カンパニー |
閉端dnaおよび切断可能脂質を含む脂質ナノ粒子組成物ならびにそれらの使用方法
|
|
BR112022004759A2
(pt)
|
2019-09-19 |
2022-06-21 |
Modernatx Inc |
Composições e compostos lipídicos com cauda ramificada para entrega intracelular de agentes terapêuticos
|
|
EP4038189A1
(en)
|
2019-10-04 |
2022-08-10 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing ugt1a1 gene expression
|
|
US12486512B2
(en)
|
2019-10-18 |
2025-12-02 |
Alnylam Pharmaceuticals, Inc. |
Solute carrier family member iRNA compositions and methods of use thereof
|
|
AU2020369515A1
(en)
|
2019-10-22 |
2022-04-21 |
Alnylam Pharmaceuticals, Inc. |
Complement component C3 iRNA compositions and methods of use thereof
|
|
JP7798763B2
(ja)
|
2019-10-25 |
2026-01-14 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
C5関連疾患の治療または予防のための投与レジメン
|
|
CN119499394A
(zh)
|
2019-11-01 |
2025-02-25 |
阿尔尼拉姆医药品有限公司 |
亨廷顿(HTT)iRNA药剂组合物及其使用方法
|
|
WO2021087325A1
(en)
|
2019-11-01 |
2021-05-06 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajb1-prkaca fusion gene expression
|
|
TWI877247B
(zh)
|
2019-11-13 |
2025-03-21 |
美商阿尼拉製藥公司 |
用於治療血管收縮素原相關病症之方法及組成物
|
|
EP4328309B1
(en)
|
2019-11-15 |
2025-07-02 |
FUJIFILM Corporation |
Lipid composition
|
|
AU2020385683A1
(en)
|
2019-11-18 |
2022-06-30 |
Janssen Biotech, Inc. |
Vaccines based on mutant CALR and JAK2 and their uses
|
|
CA3154774A1
(en)
|
2019-11-22 |
2021-05-27 |
Generation Bio Co. |
Ionizable lipids and nanoparticle compositions thereof
|
|
WO2021102373A1
(en)
|
2019-11-22 |
2021-05-27 |
Alnylam Pharmaceuticals, Inc. |
Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
|
|
PH12022551394A1
(en)
|
2019-12-13 |
2023-09-11 |
Alnylam Pharmaceuticals Inc |
Human chromosome 9 open reading frame 72 (c9orf72) irna agent compositions and methods of use thereof
|
|
TW202138559A
(zh)
|
2019-12-16 |
2021-10-16 |
美商阿尼拉製藥公司 |
含類PATATIN磷脂酶結構域3(PNPLA3)iRNA組成物及其使用方法
|
|
EP4076647A1
(en)
|
2019-12-20 |
2022-10-26 |
CureVac AG |
Lipid nanoparticles for delivery of nucleic acids
|
|
CN115175894B
(zh)
|
2020-01-09 |
2024-09-06 |
盖德治疗有限责任公司 |
纳米材料
|
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
|
JP7793525B2
(ja)
|
2020-02-04 |
2026-01-05 |
キュアバック エスイー |
コロナウイルスワクチン
|
|
US12194089B2
(en)
|
2020-02-04 |
2025-01-14 |
CureVac SE |
Coronavirus vaccine
|
|
AU2021220765A1
(en)
|
2020-02-10 |
2022-09-01 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing VEGF-A expression
|
|
JP7735288B2
(ja)
|
2020-02-18 |
2025-09-08 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
アポリポタンパク質C3(APOC3)iRNA組成物およびその使用法
|
|
WO2021178510A1
(en)
|
2020-03-03 |
2021-09-10 |
Arcturus Therapeutics, Inc. |
Compositions and methods for the treatment of ornithine transcarbamylase deficiency
|
|
EP4114947A1
(en)
|
2020-03-05 |
2023-01-11 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
|
|
WO2021178736A1
(en)
|
2020-03-06 |
2021-09-10 |
Alnylam Pharmaceuticals, Inc. |
KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
JP2023517644A
(ja)
|
2020-03-09 |
2023-04-26 |
アークトゥラス・セラピューティクス・インコーポレイテッド |
コロナウイルスワクチン組成物及び方法
|
|
CA3172591A1
(en)
|
2020-03-24 |
2021-09-30 |
Douglas Anthony KERR |
Non-viral dna vectors and uses thereof for expressing gaucher therapeutics
|
|
IL296660A
(en)
|
2020-03-24 |
2022-11-01 |
Generation Bio Co |
Non-viral dna vectors and uses thereof for expressing factor ix therapeutics
|
|
WO2021195307A1
(en)
|
2020-03-26 |
2021-09-30 |
Alnylam Pharmaceuticals, Inc. |
Coronavirus irna compositions and methods of use thereof
|
|
US12534435B2
(en)
|
2020-03-27 |
2026-01-27 |
Generation Bio Co. |
Lipids and nanoparticle compositions thereof
|
|
IL296781A
(en)
|
2020-03-30 |
2022-11-01 |
BioNTech SE |
Rna compositions targeting claudin-18.2
|
|
US20230190785A1
(en)
|
2020-03-30 |
2023-06-22 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajc15 gene expression
|
|
EP4127134A4
(en)
|
2020-04-01 |
2024-07-31 |
Alnylam Pharmaceuticals, Inc. |
COMPOSITIONS OF ALPHA-2A ADRENERGIC RECEPTOR (ADRA2A) ARNI AGENTS AND METHODS OF USE THEREOF
|
|
US11773391B2
(en)
|
2020-04-01 |
2023-10-03 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Therapeutic and diagnostic target for SARS-CoV-2 and COVID-19
|
|
AR121769A1
(es)
|
2020-04-06 |
2022-07-06 |
Alnylam Pharmaceuticals Inc |
Composiciones y métodos para el silenciamiento de la expresión de myoc
|
|
WO2021206922A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
|
|
EP4133076A1
(en)
|
2020-04-07 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Angiotensin-converting enzyme 2 (ace2) irna compositions and methods of use thereof
|
|
CA3179678A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing scn9a expression
|
|
WO2021205077A1
(en)
|
2020-04-09 |
2021-10-14 |
Finncure Oy |
Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
|
|
US12194157B2
(en)
|
2020-04-09 |
2025-01-14 |
Finncure Oy |
Carrier for targeted delivery to a host
|
|
US11547673B1
(en)
*
|
2020-04-22 |
2023-01-10 |
BioNTech SE |
Coronavirus vaccine
|
|
KR20230018377A
(ko)
|
2020-04-27 |
2023-02-07 |
알닐람 파마슈티칼스 인코포레이티드 |
아포지질단백질 e (apoe) irna 제제 조성물 및 이의 사용 방법
|
|
JP2023523345A
(ja)
|
2020-04-27 |
2023-06-02 |
シックスフォールド バイオサイエンス リミテッド |
モジュール官能基を有する核酸ナノ粒子を含有する組成物
|
|
BR112022021136A2
(pt)
|
2020-04-30 |
2022-11-29 |
Alnylam Pharmaceuticals Inc |
Composições de irna de fator b de complemento (cfb) e métodos de uso das mesmas
|
|
EP4143217A4
(en)
|
2020-05-01 |
2024-10-02 |
Arcturus Therapeutics, Inc. |
NUCLEIC ACIDS AND METHODS FOR TREATING CYSTIC FIBROSIS
|
|
WO2021231675A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
|
|
EP4150090A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of otoferlin (otof)
|
|
WO2021231673A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
|
|
WO2021231691A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi)
|
|
EP4150078A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
|
|
WO2021231680A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
|
|
WO2021231679A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
|
|
EP4150077A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
|
|
JP2023526422A
(ja)
|
2020-05-20 |
2023-06-21 |
フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー |
コロナウイルス抗原組成物及びそれらの使用
|
|
EP4153223A1
(en)
|
2020-05-20 |
2023-03-29 |
Flagship Pioneering Innovations VI, LLC |
Immunogenic compositions and uses thereof
|
|
EP4153746A1
(en)
|
2020-05-21 |
2023-03-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting marc1 gene expression
|
|
CN116322758A
(zh)
|
2020-05-29 |
2023-06-23 |
库尔维科欧洲股份公司 |
基于核酸的组合疫苗
|
|
CN116018405A
(zh)
|
2020-05-29 |
2023-04-25 |
旗舰先锋创新Vi有限责任公司 |
Trem组合物及其相关方法
|
|
AU2021281453A1
(en)
|
2020-05-29 |
2022-11-17 |
Flagship Pioneering Innovations Vi, Llc. |
Trem compositions and methods relating thereto
|
|
AR122534A1
(es)
|
2020-06-03 |
2022-09-21 |
Triplet Therapeutics Inc |
Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3
|
|
JP2023529903A
(ja)
|
2020-06-09 |
2023-07-12 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
GPAM(グリセロール-3-リン酸アシルトランスフェラーゼ1、ミトコンドリア)発現をサイレンシングするためのsiRNA組成物および方法
|
|
EP4162050A1
(en)
|
2020-06-09 |
2023-04-12 |
Alnylam Pharmaceuticals, Inc. |
Rnai compositions and methods of use thereof for delivery by inhalation
|
|
JP2023530974A
(ja)
|
2020-06-15 |
2023-07-20 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
筋ジストロフィーのためのアデノ随伴ウイルスベクター送達
|
|
TW202214856A
(zh)
|
2020-06-18 |
2022-04-16 |
美商阿尼拉製藥公司 |
黃嘌呤脫氫酶(XDH)iRNA組成物及其使用之方法
|
|
WO2025056938A1
(en)
|
2023-09-11 |
2025-03-20 |
BioNTech SE |
Rna compositions for delivery of incretin agents
|
|
WO2022009052A2
(en)
|
2020-07-06 |
2022-01-13 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
|
IL299571A
(en)
|
2020-07-08 |
2023-02-01 |
Janssen Sciences Ireland Unlimited Co |
Rna replicon vaccines against hbv
|
|
CN115768438A
(zh)
*
|
2020-07-10 |
2023-03-07 |
盖纳万科学有限公司 |
用于向肺递送治疗剂的脂质纳米颗粒
|
|
DK4182297T3
(da)
|
2020-07-16 |
2025-12-01 |
Acuitas Therapeutics Inc |
Kationiske lipider til brug i lipid-nanopartikler
|
|
EP4189098A1
(en)
|
2020-07-27 |
2023-06-07 |
Anjarium Biosciences AG |
Compositions of dna molecules, methods of making therefor, and methods of use thereof
|
|
EP4172194A1
(en)
|
2020-07-31 |
2023-05-03 |
CureVac SE |
Nucleic acid encoded antibody mixtures
|
|
CN116171150A
(zh)
|
2020-08-14 |
2023-05-26 |
阿克丘勒斯治疗公司 |
冻干脂质纳米颗粒的方法
|
|
US11406703B2
(en)
|
2020-08-25 |
2022-08-09 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
US20240066114A1
(en)
|
2020-08-31 |
2024-02-29 |
CureVac SE |
Multivalent nucleic acid based coronavirus vaccines
|
|
MX2023002439A
(es)
|
2020-09-03 |
2023-05-09 |
Flagship Pioneering Innovations Vi Llc |
Composiciones immunogénicas y usos de las mismas.
|
|
CN116056728A
(zh)
|
2020-09-14 |
2023-05-02 |
富士胶片株式会社 |
脂质组合物
|
|
JP2023549011A
(ja)
|
2020-09-15 |
2023-11-22 |
ヴァーヴ・セラピューティクス,インコーポレーテッド |
遺伝子編集のための脂質製剤
|
|
TW202228784A
(zh)
|
2020-09-23 |
2022-08-01 |
奧地利商艾柏力維亞生技有限公司 |
用以於一患者中螯合非預期的抗peg抗體的化合物
|
|
CZ310613B6
(cs)
|
2020-09-23 |
2026-01-28 |
Ústav organické chemie a biochemie AV ČR, v. v. i. |
Lipidoidy pro transfekci nukleových kyselin a jejich použití
|
|
WO2022066847A1
(en)
|
2020-09-24 |
2022-03-31 |
Alnylam Pharmaceuticals, Inc. |
Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
|
|
WO2022076291A1
(en)
|
2020-10-05 |
2022-04-14 |
Alnylam Pharmaceuticals, Inc. |
G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof
|
|
EP4229208A4
(en)
|
2020-10-14 |
2024-10-30 |
George Mason Research Foundation, Inc. |
METHOD FOR THE PRODUCTION OF LIPID DNANOPARTICLES AND COMPOSITIONS THEREOF
|
|
CA3198823A1
(en)
|
2020-10-21 |
2022-04-28 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating primary hyperoxaluria
|
|
WO2022087329A1
(en)
|
2020-10-23 |
2022-04-28 |
Alnylam Pharmaceuticals, Inc. |
Mucin 5b (muc5b) irna compositions and methods of use thereof
|
|
TW202233232A
(zh)
|
2020-11-06 |
2022-09-01 |
法商賽諾菲公司 |
遞送mRNA疫苗的脂質奈米顆粒
|
|
IL302709A
(en)
|
2020-11-13 |
2023-07-01 |
Alnylam Pharmaceuticals Inc |
Coagulation factor iRNA compositions (F5) and methods of using them
|
|
US11591544B2
(en)
|
2020-11-25 |
2023-02-28 |
Akagera Medicines, Inc. |
Ionizable cationic lipids
|
|
AU2021393417A1
(en)
|
2020-12-01 |
2023-06-29 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
|
|
EP4256054A1
(en)
|
2020-12-03 |
2023-10-11 |
Scribe Therapeutics Inc. |
Engineered class 2 type v crispr systems
|
|
EP4259795A1
(en)
|
2020-12-08 |
2023-10-18 |
Alnylam Pharmaceuticals, Inc. |
Coagulation factor x (f10) irna compositions and methods of use thereof
|
|
GB2603454A
(en)
|
2020-12-09 |
2022-08-10 |
Ucl Business Ltd |
Novel therapeutics for the treatment of neurodegenerative disorders
|
|
EP4262819A4
(en)
|
2020-12-21 |
2024-12-04 |
Beam Therapeutics Inc. |
NANOMATERIALS WITH ESTER-BOUND ACETALS
|
|
WO2022137133A1
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Rna vaccine against sars-cov-2 variants
|
|
US20240156946A1
(en)
|
2020-12-22 |
2024-05-16 |
CureVac SE |
Rna vaccine against sars-cov-2 variants
|
|
CA3205827A1
(en)
*
|
2020-12-22 |
2022-06-30 |
Cornell University |
Zwitterionic lipid nanoparticle compositions, and methods of use
|
|
WO2022135993A2
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
|
|
KR20230135585A
(ko)
|
2020-12-23 |
2023-09-25 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
변형된 trem의 조성물 및 이의 용도
|
|
US20220202952A1
(en)
*
|
2020-12-28 |
2022-06-30 |
Industrial Technology Research Institute |
Immunostimulatory lipoplex, pharmaceutical composition including immunostimulatory lipoplex, and uses thereof
|
|
JP2024501022A
(ja)
|
2020-12-28 |
2024-01-10 |
アークトゥルス セラピューティクス, インコーポレイテッド |
Hbvを標的とする転写活性化因子様エフェクターヌクレアーゼ(talen)
|
|
EP4274896A1
(en)
|
2021-01-05 |
2023-11-15 |
Alnylam Pharmaceuticals, Inc. |
Complement component 9 (c9) irna compositions and methods of use thereof
|
|
WO2022159463A1
(en)
|
2021-01-20 |
2022-07-28 |
Beam Therapeutics Inc. |
Nanomaterials
|
|
CN116847853A
(zh)
|
2021-01-20 |
2023-10-03 |
比姆医疗股份有限公司 |
包括可生物降解的特征的纳米材料
|
|
WO2022157548A1
(en)
|
2021-01-24 |
2022-07-28 |
Forrest Michael David |
Inhibitors of atp synthase - cosmetic and therapeutic uses
|
|
EP4087938A2
(en)
|
2021-01-27 |
2022-11-16 |
CureVac AG |
Method of reducing the immunostimulatory properties of in vitro transcribed rna
|
|
TW202245835A
(zh)
|
2021-02-04 |
2022-12-01 |
美商默沙東有限責任公司 |
用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
|
|
EP4291654A2
(en)
|
2021-02-12 |
2023-12-20 |
Alnylam Pharmaceuticals, Inc. |
Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases
|
|
US11524023B2
(en)
|
2021-02-19 |
2022-12-13 |
Modernatx, Inc. |
Lipid nanoparticle compositions and methods of formulating the same
|
|
JP2024509783A
(ja)
|
2021-02-25 |
2024-03-05 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
プリオンタンパク質(prnp)irna組成物およびその使用方法
|
|
CN116887812A
(zh)
|
2021-02-26 |
2023-10-13 |
埃泽瑞斯公司 |
用于气溶胶形成的制剂以及用于递送核酸的气溶胶
|
|
AU2022226098A1
(en)
|
2021-02-26 |
2023-08-24 |
Alnylam Pharmaceuticals, Inc. |
KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
IL305418A
(en)
|
2021-03-04 |
2023-10-01 |
Alnylam Pharmaceuticals Inc |
Angiopoietin-like 3 (ANGPTL3) IRNA compositions and methods of using them
|
|
EP4305169A1
(en)
|
2021-03-12 |
2024-01-17 |
Alnylam Pharmaceuticals, Inc. |
Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
|
|
US20240181038A1
(en)
|
2021-03-26 |
2024-06-06 |
Glaxosmithkline Biologicals Sa |
Immunogenic compositions
|
|
JP2024511092A
(ja)
|
2021-03-26 |
2024-03-12 |
ミナ セラピューティクス リミテッド |
TMEM173saRNA組成物及び使用方法
|
|
MX2023011466A
(es)
|
2021-03-29 |
2024-02-01 |
Alnylam Pharmaceuticals Inc |
Composiciones de agentes de ácido ribonucleico de interferencia (arni) de huntingtina (htt) y métodos de uso de estas.
|
|
WO2022207862A2
(en)
|
2021-03-31 |
2022-10-06 |
Curevac Ag |
Syringes containing pharmaceutical compositions comprising rna
|
|
CA3214085A1
(en)
|
2021-03-31 |
2022-10-06 |
Darby Rye Schmidt |
Thanotransmission polypeptides and their use in treating cancer
|
|
WO2022212153A1
(en)
|
2021-04-01 |
2022-10-06 |
Alnylam Pharmaceuticals, Inc. |
Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
|
|
DK4319803T3
(da)
|
2021-04-08 |
2025-12-15 |
Vaxthera Sas |
Coronavirusvaccine omfattende et mosaikprotein
|
|
AU2022260111A1
(en)
|
2021-04-20 |
2023-11-30 |
Anjarium Biosciences Ag |
Compositions of dna molecules encoding amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase, methods of making thereof, and methods of use thereof
|
|
WO2022225368A1
(ko)
|
2021-04-22 |
2022-10-27 |
(주)인벤티지랩 |
지질 나노입자의 제조 방법 및 이의 제조 장치
|
|
TW202309280A
(zh)
|
2021-04-26 |
2023-03-01 |
美商艾拉倫製藥股份有限公司 |
跨膜絲胺酸蛋白酶6(TMPRSS6)iRNA組成物及其使用方法
|
|
EP4329884A1
(en)
|
2021-04-27 |
2024-03-06 |
Generation Bio Co. |
Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
|
|
AU2022264509A1
(en)
|
2021-04-27 |
2023-12-14 |
Generation Bio Co. |
Non-viral dna vectors expressing therapeutic antibodies and uses thereof
|
|
EP4330396A1
(en)
|
2021-04-29 |
2024-03-06 |
Alnylam Pharmaceuticals, Inc. |
Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof
|
|
CA3171589A1
(en)
|
2021-05-03 |
2022-11-03 |
Moritz THRAN |
Improved nucleic acid sequence for cell type specific expression
|
|
EP4341401A1
(en)
|
2021-05-18 |
2024-03-27 |
Alnylam Pharmaceuticals, Inc. |
Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof
|
|
US20240263177A1
(en)
|
2021-05-20 |
2024-08-08 |
Korro Bio, Inc. |
Methods and Compositions for Adar-Mediated Editing
|
|
WO2022244831A1
(en)
|
2021-05-21 |
2022-11-24 |
Okinawa Institute Of Science And Technology School Corporation |
Coronavirus vaccine suitable for elderly individuals
|
|
WO2022256283A2
(en)
|
2021-06-01 |
2022-12-08 |
Korro Bio, Inc. |
Methods for restoring protein function using adar
|
|
EP4347823A1
(en)
|
2021-06-02 |
2024-04-10 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
|
TW202308663A
(zh)
|
2021-06-04 |
2023-03-01 |
美商艾拉倫製藥股份有限公司 |
人類染色體9開讀框72(C9ORF72)iRNA劑組成物及其使用方法
|
|
EP4351541A2
(en)
|
2021-06-08 |
2024-04-17 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating or preventing stargardt's disease and/or retinal binding protein 4 (rbp4)-associated disorders
|
|
US20240271162A1
(en)
|
2021-06-11 |
2024-08-15 |
LifeEDIT Therapeutics, Inc. |
Rna polymerase iii promoters and methods of use
|
|
EP4353268A1
(en)
|
2021-06-11 |
2024-04-17 |
Nibec Co., Ltd. |
Nanoparticle comprising peptide-lipid conjugate for delivering oligonucleotide into target cell and pharmaceutical composition comprising same
|
|
CN117642380A
(zh)
|
2021-06-14 |
2024-03-01 |
世代生物公司 |
阳离子脂质及其组合物
|
|
IL309578A
(en)
|
2021-06-22 |
2024-02-01 |
Bio Trip B V |
Nanoparticles containing nucleic acid
|
|
US20250034564A1
(en)
|
2021-06-29 |
2025-01-30 |
Korro Bio, Inc. |
Methods and Compositions for ADAR-Mediated Editing
|
|
US20230194709A9
(en)
|
2021-06-29 |
2023-06-22 |
Seagate Technology Llc |
Range information detection using coherent pulse sets with selected waveform characteristics
|
|
AU2022303164A1
(en)
|
2021-06-30 |
2024-01-18 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
|
|
JP2024527584A
(ja)
|
2021-07-09 |
2024-07-25 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
CNS送達のためのBis-RNAi化合物
|
|
WO2023288287A2
(en)
|
2021-07-15 |
2023-01-19 |
Turn Biotechnologies, Inc. |
Synthetic, persistent rna constructs and methods of use for cell rejuvenation and for treatment
|
|
WO2023288288A1
(en)
|
2021-07-15 |
2023-01-19 |
Turn Biotechnologies, Inc. |
Synthetic, persistent rna constructs with on/off mechanism for controlled expression and methods of use
|
|
US20230042860A1
(en)
|
2021-07-15 |
2023-02-09 |
Turn Biotechnologies, Inc. |
Polycistronic expression vectors
|
|
CA3226887A1
(en)
|
2021-07-21 |
2023-01-26 |
Alnylam Pharmaceuticals, Inc. |
Metabolic disorder-associated target gene irna compositions and methods of use thereof
|
|
TW202325312A
(zh)
|
2021-07-23 |
2023-07-01 |
美商艾拉倫製藥股份有限公司 |
β-鏈蛋白(CTNNB1)iRNA組成物及其使用方法
|
|
EP4377457A1
(en)
|
2021-07-26 |
2024-06-05 |
Flagship Pioneering Innovations VI, LLC |
Trem compositions and uses thereof
|
|
CA3227440A1
(en)
|
2021-07-27 |
2023-02-02 |
Stand Therapeutics Co., Ltd. |
Peptide tag and nucleic acid encoding same
|
|
EP4377458A1
(en)
|
2021-07-29 |
2024-06-05 |
Alnylam Pharmaceuticals, Inc. |
3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof
|
|
US20240342206A1
(en)
|
2021-07-30 |
2024-10-17 |
CureVac SE |
mRNAS FOR TREATMENT OR PROPHYLAXIS OF LIVER DISEASES
|
|
CA3227852A1
(en)
|
2021-08-03 |
2023-02-09 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna compositions and methods of use thereof
|
|
AU2022324003A1
(en)
|
2021-08-04 |
2024-02-08 |
Alnylam Pharmaceuticals, Inc. |
iRNA COMPOSITIONS AND METHODS FOR SILENCING ANGIOTENSINOGEN (AGT)
|
|
MX2024001573A
(es)
|
2021-08-13 |
2024-02-14 |
Alnylam Pharmaceuticals Inc |
Composiciones de acido ribonucleico de interferencia (arni) contra el factor xii (f12) y sus metodos de uso.
|
|
WO2023023055A1
(en)
|
2021-08-16 |
2023-02-23 |
Renagade Therapeutics Management Inc. |
Compositions and methods for optimizing tropism of delivery systems for rna
|
|
JP2024538859A
(ja)
|
2021-08-31 |
2024-10-24 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
細胞死誘導DFFA様エフェクターB(CIDEB)iRNA組成物およびその使用方法
|
|
US20240398933A1
(en)
|
2021-09-03 |
2024-12-05 |
CureVac SE |
Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
|
|
EP4395748A1
(en)
|
2021-09-03 |
2024-07-10 |
CureVac SE |
Novel lipid nanoparticles for delivery of nucleic acids
|
|
TW202328067A
(zh)
|
2021-09-14 |
2023-07-16 |
美商雷納嘉德醫療管理公司 |
環狀脂質及其使用方法
|
|
CN118317944A
(zh)
|
2021-09-14 |
2024-07-09 |
雷纳嘉德医疗管理公司 |
非环状脂质及其使用方法
|
|
AR127073A1
(es)
|
2021-09-17 |
2023-12-13 |
Flagship Pioneering Innovations Vi Llc |
Composiciones y métodos para producir polirribonucleótidos circulares
|
|
JP2024535850A
(ja)
|
2021-09-17 |
2024-10-02 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
補体成分(C3)をサイレンシングするためのiRNA組成物および方法
|
|
JP2024535888A
(ja)
|
2021-09-20 |
2024-10-02 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
インヒビンサブユニットベータe(inhbe)モジュレーター組成物およびその使用方法
|
|
JP2024534523A
(ja)
|
2021-09-21 |
2024-09-20 |
スクライブ・セラピューティクス・インコーポレイテッド |
操作されたcasxリプレッサー系
|
|
MX2024003519A
(es)
|
2021-09-24 |
2024-04-01 |
Alnylam Pharmaceuticals Inc |
Composiciones de agentes de acido ribonucleico de interferencia (arni) de proteina tau asociada a microtubulos (mapt) y sus metodos de uso.
|
|
KR20240101590A9
(ko)
|
2021-10-15 |
2025-12-10 |
알닐람 파마슈티칼스 인코포레이티드 |
간외 전달 irna 조성물 및 이를 이용하는 방법
|
|
AU2022370530A1
(en)
|
2021-10-18 |
2024-05-02 |
Flagship Pioneering Innovations Vi, Llc |
Compositions and methods for purifying polyribonucleotides
|
|
WO2023069603A1
(en)
|
2021-10-22 |
2023-04-27 |
Korro Bio, Inc. |
Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
|
|
US20250027108A1
(en)
|
2021-10-29 |
2025-01-23 |
CureVac SE |
Improved circular rna for expressing therapeutic proteins
|
|
CA3234636A1
(en)
|
2021-10-29 |
2023-05-04 |
Alnylam Pharmaceuticals, Inc. |
Complement factor b (cfb) irna compositions and methods of use thereof
|
|
JP2024541974A
(ja)
|
2021-10-29 |
2024-11-13 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
ハンチンチン(HTT)iRNA剤組成物およびその使用方法
|
|
CA3237482A1
(en)
|
2021-11-03 |
2023-05-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Precise genome editing using retrons
|
|
TW202334080A
(zh)
|
2021-11-08 |
2023-09-01 |
美商歐納醫療公司 |
用於遞送環狀聚核苷酸之脂質奈米粒子組合物
|
|
KR102772764B1
(ko)
|
2021-11-10 |
2025-02-27 |
주식회사 에스엠엘바이오팜 |
트레할로즈 유도체 및 신규 구조 유지 화합물을 포함하는 핵산 의약품 전달용 지질나노입자의 약학 조성물
|
|
CA3238292A1
(en)
|
2021-11-16 |
2023-05-25 |
Alessandra Bartolozzi |
Novel ionizable lipids and lipid nanoparticles and methods of using the same
|
|
EP4436549A1
(en)
|
2021-11-22 |
2024-10-02 |
Sail Biomedicines, Inc. |
Novel ionizable lipids and lipid nanoparticles and methods of using the same
|
|
IL312965A
(en)
|
2021-11-24 |
2024-07-01 |
Flagship Pioneering Innovations Vi Llc |
Immunogenic compositions and their uses
|
|
JP2024541466A
(ja)
|
2021-11-24 |
2024-11-08 |
フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー |
水痘帯状疱疹ウイルス免疫原組成物及びその使用
|
|
JP2024541467A
(ja)
|
2021-11-24 |
2024-11-08 |
フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー |
コロナウイルス免疫原組成物及びそれらの使用
|
|
US12186387B2
(en)
|
2021-11-29 |
2025-01-07 |
BioNTech SE |
Coronavirus vaccine
|
|
WO2023099884A1
(en)
|
2021-12-01 |
2023-06-08 |
Mina Therapeutics Limited |
Pax6 sarna compositions and methods of use
|
|
GB202117758D0
(en)
|
2021-12-09 |
2022-01-26 |
Ucl Business Ltd |
Therapeutics for the treatment of neurodegenerative disorders
|
|
WO2023114943A2
(en)
|
2021-12-16 |
2023-06-22 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
AU2022413687A1
(en)
|
2021-12-17 |
2024-06-27 |
Flagship Pioneering Innovations Vi, Llc |
Methods for enrichment of circular rna under denaturing conditions
|
|
WO2023121965A1
(en)
|
2021-12-20 |
2023-06-29 |
Beam Therapeutics Inc. |
Nanomaterial comprising diamines
|
|
WO2023121971A1
(en)
|
2021-12-20 |
2023-06-29 |
Beam Therapeutics Inc. |
Nanomaterials comprising tetravalent lipid compounds
|
|
EP4452935A1
(en)
|
2021-12-20 |
2024-10-30 |
Beam Therapeutics Inc. |
Ionizable amine lipids and lipid nanoparticles
|
|
EP4452930A1
(en)
|
2021-12-20 |
2024-10-30 |
Beam Therapeutics Inc. |
Ionizable amine and ester lipids and lipid nanoparticles
|
|
EP4452942A1
(en)
|
2021-12-20 |
2024-10-30 |
Beam Therapeutics Inc. |
Nanomaterials comprising disulfides
|
|
EP4453201A1
(en)
|
2021-12-22 |
2024-10-30 |
Flagship Pioneering Innovations VI, LLC |
Compositions and methods for purifying polyribonucleotides
|
|
US20230201817A1
(en)
|
2021-12-23 |
2023-06-29 |
Biontech Delivery Technologies Gmbh |
Modular drug production system
|
|
JP2025500358A
(ja)
|
2021-12-23 |
2025-01-09 |
フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー |
抗膜融合ポリペプチドをコードする環状ポリリボヌクレオチド
|
|
WO2023122752A1
(en)
|
2021-12-23 |
2023-06-29 |
Renagade Therapeutics Management Inc. |
Constrained lipids and methods of use thereof
|
|
WO2023135273A2
(en)
|
2022-01-14 |
2023-07-20 |
Anjarium Biosciences Ag |
Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof
|
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
EP4469575A2
(en)
|
2022-01-24 |
2024-12-04 |
Alnylam Pharmaceuticals, Inc. |
Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
|
|
CN118660708A
(zh)
|
2022-01-25 |
2024-09-17 |
公益财团法人川崎市产业振兴财团 |
用于经皮给药的含有rna的组合物和该组合物的给药方法
|
|
WO2023144193A1
(en)
|
2022-01-25 |
2023-08-03 |
CureVac SE |
Mrnas for treatment of hereditary tyrosinemia type i
|
|
US20250345416A1
(en)
|
2022-01-27 |
2025-11-13 |
BioNTech SE |
Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
|
|
EP4469091A1
(en)
|
2022-01-28 |
2024-12-04 |
CureVac SE |
Nucleic acid encoded transcription factor inhibitors
|
|
EP4482962A1
(en)
|
2022-02-24 |
2025-01-01 |
IO Biotech ApS |
Nucleotide delivery of cancer therapy
|
|
WO2023170435A1
(en)
|
2022-03-07 |
2023-09-14 |
Mina Therapeutics Limited |
Il10 sarna compositions and methods of use
|
|
CN119072330A
(zh)
|
2022-03-14 |
2024-12-03 |
世代生物公司 |
异源初免加强疫苗组合物和使用方法
|
|
EP4691500A2
(en)
|
2022-03-15 |
2026-02-11 |
FUJIFILM Corporation |
Lipid composition
|
|
US11951177B2
(en)
|
2022-03-23 |
2024-04-09 |
Nanovation Therapeutics Inc. |
High sterol-containing lipid nanoparticles
|
|
US20250205167A1
(en)
|
2022-03-25 |
2025-06-26 |
Sail Biomedicines, Inc. |
Novel ionizable lipids and lipid nanoparticles and methods of using the same
|
|
US12011507B2
(en)
|
2022-04-01 |
2024-06-18 |
Nanovation Therapeutics Inc. |
MRNA delivery composition
|
|
CA3255225A1
(en)
|
2022-04-04 |
2023-10-12 |
The Regents Of The University Of California |
COMPOSITIONS AND METHODS OF GENETIC COMPLEMENTATION
|
|
AU2023251104A1
(en)
|
2022-04-07 |
2024-10-17 |
Renagade Therapeutics Management Inc. |
Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents
|
|
JP2025511756A
(ja)
|
2022-04-08 |
2025-04-16 |
フラッグシップ パイオニアリング イノベーションズ セブン,エルエルシー |
ワクチン及び関連する方法
|
|
EP4509529A1
(en)
|
2022-04-12 |
2025-02-19 |
Riken |
Antibody used to treat coronavirus infection
|
|
KR20250005214A
(ko)
|
2022-04-13 |
2025-01-09 |
우니버시타트 아우토노마 데 바르셀로나 |
클로토 단백질을 발현시키는 유전자 요법을 통한 신경근 질환의 치료
|
|
CN118900914A
(zh)
|
2022-04-27 |
2024-11-05 |
上海瑞宏迪医药有限公司 |
核酸构建体及其应用
|
|
CA3257006A1
(en)
|
2022-05-09 |
2023-11-16 |
Flagship Pioneering Innovations Vi, Llc |
TREM COMPOSITIONS AND METHODS OF USE FOR TREATING PROLIFERATIVE DISORDERS
|
|
CN119487196A
(zh)
|
2022-05-13 |
2025-02-18 |
旗舰创业创新七公司 |
双链dna组合物及相关方法
|
|
CN119013405A
(zh)
|
2022-05-13 |
2024-11-22 |
上海瑞宏迪医药有限公司 |
包含utr的核酸构建体及其应用
|
|
JP2025516674A
(ja)
|
2022-05-13 |
2025-05-30 |
ビオンテック エスエー |
Hivを標的とするrna組成物
|
|
WO2023218420A1
(en)
|
2022-05-13 |
2023-11-16 |
Janssen Pharmaceuticals, Inc. |
Mrna compositions for inducing latent hiv-1 reversal
|
|
CN119630433A
(zh)
|
2022-05-23 |
2025-03-14 |
逻辑生物治疗公司 |
基因疗法组合物及其使用方法
|
|
US20250345407A1
(en)
|
2022-05-25 |
2025-11-13 |
CureVac SE |
Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
|
|
KR20250031230A
(ko)
|
2022-05-25 |
2025-03-06 |
아카제라 메디신즈, 인크. |
핵산 전달을 위한 지질 나노입자 및 이의 사용 방법
|
|
IL316504A
(en)
|
2022-05-25 |
2024-12-01 |
BioNTech SE |
RNA compositions for the delivery of monkeypox antigens and related methods
|
|
JP2025518221A
(ja)
|
2022-05-30 |
2025-06-12 |
ビオンテック・ソシエタス・エウロパエア |
核酸の送達のための複合体
|
|
US20250333767A1
(en)
|
2022-06-02 |
2025-10-30 |
Scribe Therapeutics Inc. |
Engineered class 2 type v crispr systems
|
|
CA3258109A1
(en)
|
2022-06-03 |
2023-12-07 |
Bio-Trip B.V. |
LIPID NANOPARTICLES BASED ON MULTIPURPOSE MOLECULES FOR THE ADMINISTRATION OF NUCLEIC ACIDS
|
|
EP4314267A1
(en)
|
2022-06-07 |
2024-02-07 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of pcsk9
|
|
EP4536819A1
(en)
|
2022-06-07 |
2025-04-16 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of pcsk9
|
|
AU2023283348A1
(en)
|
2022-06-07 |
2025-01-09 |
Generation Bio Co. |
Lipid nanoparticle compositions and uses thereof
|
|
EP4544043A1
(en)
|
2022-06-22 |
2025-04-30 |
Flagship Pioneering Innovations VI, LLC |
Compositions of modified trems and uses thereof
|
|
US11878055B1
(en)
|
2022-06-26 |
2024-01-23 |
BioNTech SE |
Coronavirus vaccine
|
|
AU2023311964A1
(en)
|
2022-07-18 |
2025-01-30 |
Renagade Therapeutics Management Inc. |
Gene editing components, systems, and methods of use
|
|
AU2023311822A1
(en)
|
2022-07-20 |
2025-01-09 |
Beam Therapeutics Inc. |
Nanomaterials comprising triols
|
|
CA3261283A1
(en)
|
2022-08-01 |
2024-02-08 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory Proteins and Associated Methods
|
|
WO2024035952A1
(en)
|
2022-08-12 |
2024-02-15 |
Remix Therapeutics Inc. |
Methods and compositions for modulating splicing at alternative splice sites
|
|
IL318914A
(en)
|
2022-08-12 |
2025-04-01 |
Life Edit Therapeutics Inc |
RNA-guided nucleases and active fragments and variants thereof and methods of use
|
|
WO2024039776A2
(en)
|
2022-08-18 |
2024-02-22 |
Alnylam Pharmaceuticals, Inc. |
Universal non-targeting sirna compositions and methods of use thereof
|
|
WO2024040222A1
(en)
|
2022-08-19 |
2024-02-22 |
Generation Bio Co. |
Cleavable closed-ended dna (cedna) and methods of use thereof
|
|
WO2024044723A1
(en)
|
2022-08-25 |
2024-02-29 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
JP2025529925A
(ja)
|
2022-08-26 |
2025-09-09 |
エスリス ゲーエムベーハー |
安定な脂質またはリピドイドナノ粒子懸濁液
|
|
EP4327829A1
(en)
|
2022-08-26 |
2024-02-28 |
Ethris GmbH |
Stabilization of lipid or lipidoid nanoparticle suspensions
|
|
AU2023334610A1
(en)
|
2022-08-31 |
2025-03-13 |
Sail Biomedicines, Inc. |
Novel ionizable lipids and lipid nanoparticles and methods of using the same
|
|
JPWO2024053648A1
(pl)
|
2022-09-06 |
2024-03-14 |
|
|
|
EP4569113A1
(en)
|
2022-09-15 |
2025-06-18 |
Regeneron Pharmaceuticals, Inc. |
17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
|
|
EP4342460A1
(en)
|
2022-09-21 |
2024-03-27 |
NovoArc GmbH |
Lipid nanoparticle with nucleic acid cargo
|
|
AU2023347387A1
(en)
|
2022-09-23 |
2025-04-10 |
BioNTech SE |
Compositions for delivery of liver stage antigens and related methods
|
|
IL319704A
(en)
|
2022-09-23 |
2025-05-01 |
Nchroma Bio Inc |
Compositions and methods for epigenetic regulation of HBV gene expression
|
|
WO2024063788A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of malaria antigens and related methods
|
|
WO2024063789A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of malaria antigens and related methods
|
|
AU2023347390A1
(en)
|
2022-09-23 |
2025-04-10 |
BioNTech SE |
Compositions for delivery of plasmodium csp antigens and related methods
|
|
JP2025532686A
(ja)
|
2022-09-26 |
2025-10-01 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
インフルエンザウイルスワクチン
|
|
JP2025533510A
(ja)
|
2022-09-27 |
2025-10-07 |
リゾリューション・セラピューティクス・リミテッド |
増強されたマクロファージ
|
|
WO2024073588A1
(en)
*
|
2022-09-28 |
2024-04-04 |
Board Of Regents, The University Of Texas System |
Respiratory dry powder delivery
|
|
WO2024071319A1
(en)
|
2022-09-28 |
2024-04-04 |
Okinawa Institute Of Science And Technology School Corporation |
Composition comprising isolated or enriched phosphoenolpyruvate or a salt thereof
|
|
EP4598946A1
(en)
|
2022-10-05 |
2025-08-13 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
|
IL319682A
(en)
|
2022-10-06 |
2025-05-01 |
BioNTech SE |
RNA complexes targeting claudin-18.2
|
|
WO2024074211A1
(en)
|
2022-10-06 |
2024-04-11 |
BioNTech SE |
Rna compositions targeting claudin-18.2
|
|
WO2024085149A1
(ja)
|
2022-10-18 |
2024-04-25 |
第一三共株式会社 |
テイラー反応装置及びカプセル粒子の製造方法
|
|
WO2024083345A1
(en)
|
2022-10-21 |
2024-04-25 |
BioNTech SE |
Methods and uses associated with liquid compositions
|
|
US12186389B2
(en)
|
2022-10-28 |
2025-01-07 |
Glaxosmithkline Biologicals Sa |
Nucleic acid base vaccine against emerging SARS-CoV-2 variants
|
|
WO2024097664A1
(en)
|
2022-10-31 |
2024-05-10 |
Flagship Pioneering Innovations Vi, Llc |
Compositions and methods for purifying polyribonucleotides
|
|
WO2024102762A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
JP2025537178A
(ja)
|
2022-11-08 |
2025-11-14 |
オーナ セラピューティクス, インコーポレイテッド |
環状rna組成物
|
|
TW202425959A
(zh)
|
2022-11-08 |
2024-07-01 |
美商歐納醫療公司 |
遞送多核苷酸的脂質及奈米顆粒組合物
|
|
TW202434728A
(zh)
|
2022-11-08 |
2024-09-01 |
美商旗艦先鋒創新有限責任公司 |
用於產生環狀多核糖核苷酸的組成物和方法
|
|
WO2024102954A1
(en)
|
2022-11-10 |
2024-05-16 |
Massachusetts Institute Of Technology |
Activation induced clipping system (aics)
|
|
IL320873A
(en)
|
2022-12-01 |
2025-07-01 |
Generation Bio Co |
Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions containing them
|
|
EP4626402A1
(en)
|
2022-12-01 |
2025-10-08 |
Generation Bio Co. |
Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers
|
|
CN120615013A
(zh)
|
2022-12-01 |
2025-09-09 |
世代生物公司 |
用于细胞靶向的隐形脂质纳米颗粒组合物
|
|
EP4626444A2
(en)
|
2022-12-01 |
2025-10-08 |
Generation Bio Co. |
Lipid nanoparticles comprising nucleic acids, ionizable lipids, sterols, lipid anchored polymers and helper lipids, their uses
|
|
WO2024123139A1
(ko)
|
2022-12-09 |
2024-06-13 |
주식회사 나이벡 |
타겟 세포 내로 올리고뉴클레오티드를 전달하기 위한 펩타이드 기반 결합체를 포함하는 나노입자 및 이를 포함하는 약학적 조성물
|
|
EP4631527A1
(en)
|
2022-12-09 |
2025-10-15 |
Seoul National University R&DB Foundation |
Nanoparticle comprising peptide-based conjugate for delivering mrna into b cell and t cell and uses thereof
|
|
TW202440929A
(zh)
|
2022-12-14 |
2024-10-16 |
加拿大商普羅維登斯治療控股公司 |
用於感染性疾病的組合物和方法
|
|
TW202430215A
(zh)
|
2022-12-14 |
2024-08-01 |
美商旗艦先鋒創新有限責任(Vii)公司 |
用於將治療劑遞送至骨之組成物和方法
|
|
EP4634390A2
(en)
|
2022-12-15 |
2025-10-22 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
JP2026501441A
(ja)
|
2022-12-20 |
2026-01-15 |
ユニバーシテート ユトレヒト ホールディング ビー.ブイ. |
核酸-脂質粒子
|
|
WO2024134199A1
(en)
|
2022-12-22 |
2024-06-27 |
Mina Therapeutics Limited |
Chemically modified sarna compositions and methods of use
|
|
WO2024141955A1
(en)
|
2022-12-28 |
2024-07-04 |
BioNTech SE |
Rna compositions targeting hiv
|
|
WO2024141784A2
(en)
|
2022-12-29 |
2024-07-04 |
Popvax Private Limited |
Broadly protective betacoronavirus vaccines and compositions
|
|
WO2024141786A2
(en)
|
2022-12-29 |
2024-07-04 |
Popvax Private Limited |
Multitarget vaccines and therapeutics
|
|
JP2026504827A
(ja)
|
2023-01-04 |
2026-02-10 |
インベンテージ ラボ インコーポレイテッド |
スパイラル構造を含む脂質ナノ粒子製造用チップおよびこれを用いた脂質ナノ粒子の製造方法
|
|
EP4648794A2
(en)
|
2023-01-09 |
2025-11-19 |
Flagship Pioneering Innovations VII, LLC |
Vaccines and related methods
|
|
WO2024151673A2
(en)
|
2023-01-09 |
2024-07-18 |
President And Fellows Of Harvard College |
Recombinant nucleic acid molecules and their use in wound healing
|
|
WO2024151687A1
(en)
|
2023-01-09 |
2024-07-18 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
US20240252520A1
(en)
|
2023-01-09 |
2024-08-01 |
Beth Israel Deaconess Medical Center, Inc. |
Therapeutic agents and their use for treating chronic wounds
|
|
WO2024155957A1
(en)
|
2023-01-19 |
2024-07-25 |
Altos Labs, Inc. |
Use of regeneration factors in organ transplantation
|
|
WO2024160936A1
(en)
|
2023-02-03 |
2024-08-08 |
Glaxosmithkline Biologicals Sa |
Rna formulation
|
|
TW202438515A
(zh)
|
2023-02-06 |
2024-10-01 |
美商旗艦先鋒創新有限責任(Vii)公司 |
免疫調節組合物及相關方法
|
|
EP4662311A2
(en)
|
2023-02-09 |
2025-12-17 |
Alnylam Pharmaceuticals, Inc. |
Reversir molecules and methods of use thereof
|
|
IL322468A
(en)
|
2023-02-13 |
2025-09-01 |
Flagship Pioneering Innovations Vii Llc |
Ionizable lipids containing degradable crosslinkers and lipid carriers for therapeutic compositions
|
|
GB202302092D0
(en)
|
2023-02-14 |
2023-03-29 |
Glaxosmithkline Biologicals Sa |
Analytical method
|
|
WO2024173836A2
(en)
|
2023-02-17 |
2024-08-22 |
Flagship Pioneering Innovations Vii, Llc |
Dna compositions comprising modified cytosine
|
|
IL322201A
(en)
|
2023-02-17 |
2025-09-01 |
Flagship Pioneering Innovations Vii Llc |
DNA structures containing modified uracil
|
|
AU2024233180A1
(en)
|
2023-03-08 |
2025-09-25 |
CureVac SE |
Novel lipid nanoparticle formulations for delivery of nucleic acids
|
|
EP4570269A4
(en)
|
2023-03-15 |
2025-10-22 |
United Immunity Co Ltd |
LIPID PARTICLE
|
|
KR20250162610A
(ko)
|
2023-03-15 |
2025-11-18 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
폴리리보뉴클레오티드를 포함하는 조성물 및 이의 용도
|
|
AU2024234874A1
(en)
|
2023-03-15 |
2025-10-09 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
EP4680287A1
(en)
|
2023-03-15 |
2026-01-21 |
Renagade Therapeutics Management Inc. |
Delivery of gene editing systems and methods of use thereof
|
|
CN121358494A
(zh)
|
2023-03-15 |
2026-01-16 |
旗舰创业创新第六有限责任公司 |
免疫原性组合物及其用途
|
|
WO2024194767A1
(en)
|
2023-03-17 |
2024-09-26 |
BioNTech SE |
Automated drug production system
|
|
WO2024205657A2
(en)
|
2023-03-29 |
2024-10-03 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
WO2024206620A1
(en)
|
2023-03-29 |
2024-10-03 |
Scribe Therapeutics Inc. |
Messenger rna encoding casx
|
|
AU2024248139A1
(en)
|
2023-03-29 |
2025-09-25 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of pcsk9
|
|
AU2024242151A1
(en)
|
2023-03-29 |
2025-09-25 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of lpa
|
|
TW202444914A
(zh)
|
2023-03-29 |
2024-11-16 |
美商斯奎柏治療公司 |
抑制子融合蛋白系統
|
|
WO2024209418A1
(en)
|
2023-04-07 |
2024-10-10 |
BioNTech SE |
Heating and cooling jacket for fluid vessels
|
|
EP4695393A1
(en)
|
2023-04-12 |
2026-02-18 |
Flagship Pioneering Innovations VI, LLC |
Modified trems, compositions, and related methods thereof
|
|
WO2024216128A1
(en)
|
2023-04-12 |
2024-10-17 |
Flagship Pioneering Innovations Vi, Llc |
Trems for use in correction of missense mutations
|
|
WO2024213740A1
(en)
|
2023-04-14 |
2024-10-17 |
BioNTech SE |
Vaccine mixing method, syringe and system
|
|
WO2024220746A2
(en)
|
2023-04-21 |
2024-10-24 |
Flagship Pioneering Innovations Vii, Llc |
Rnai agents targeting fatty acid synthase and related methods
|
|
EP4701657A1
(en)
|
2023-04-27 |
2026-03-04 |
GlaxoSmithKline Biologicals S.A. |
Influenza virus vaccines
|
|
EP4701658A1
(en)
|
2023-04-27 |
2026-03-04 |
GlaxoSmithKline Biologicals S.A. |
Influenza virus vaccines
|
|
WO2024228044A1
(en)
|
2023-05-03 |
2024-11-07 |
BioNTech SE |
Optimized csp variants and related methods
|
|
AU2024265158A1
(en)
|
2023-05-03 |
2025-11-06 |
BioNTech SE |
Optimized csp variants and related methods
|
|
CN121399470A
(zh)
|
2023-05-03 |
2026-01-23 |
马尼福尔德生物技术有限公司 |
用于高通量蛋白质递送、筛选和检测的方法和组合物
|
|
AU2024269222A1
(en)
|
2023-05-05 |
2025-10-09 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
WO2024230934A1
(en)
|
2023-05-11 |
2024-11-14 |
CureVac SE |
Therapeutic nucleic acid for the treatment of ophthalmic diseases
|
|
DE102023001946A1
(de)
|
2023-05-12 |
2024-11-14 |
Friedrich-Schiller-Universität Jena, Körperschaft des öffentlichen Rechts |
Nanopartikel für den Transport von Wirkstoffen mit anionischen Gruppen, Verfahren zu deren Herstellung und deren Verwendung
|
|
WO2024238700A1
(en)
|
2023-05-15 |
2024-11-21 |
Chroma Medicine, Inc. |
Compositions and methods for epigenetic regulation of hbv gene expression
|
|
EP4713453A1
(en)
|
2023-05-15 |
2026-03-25 |
nChroma Bio, Inc. |
Compositions and methods for epigenetic regulation of hbv gene expression
|
|
WO2024240962A1
(en)
|
2023-05-25 |
2024-11-28 |
Ethris Gmbh |
Gm-csf-encoding nucleic acids, pharmaceutical compositions, methods and uses thereof
|
|
CN121666232A
(zh)
|
2023-05-31 |
2026-03-13 |
开普斯坦治疗公司 |
脂质纳米颗粒制剂和组合物
|
|
WO2024258829A1
(en)
|
2023-06-12 |
2024-12-19 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
CN121311249A
(zh)
|
2023-06-22 |
2026-01-09 |
公益财团法人川崎市产业振兴财团 |
提高核酸的血中稳定性、提高靶向效率的方法
|
|
WO2025006684A1
(en)
|
2023-06-28 |
2025-01-02 |
Flagship Pioneering Innovations Vi, Llc |
Circular polyribonucleotides encoding antifusogenic polypeptides
|
|
WO2025003406A1
(en)
|
2023-06-29 |
2025-01-02 |
BioNTech SE |
Modular multiplatform system for mrna drug production
|
|
WO2025007148A1
(en)
|
2023-06-30 |
2025-01-02 |
Orna Therapeutics, Inc. |
Polymer lipid nanoparticle compositions for delivering circular polynucleotides
|
|
WO2025008774A1
(en)
|
2023-07-05 |
2025-01-09 |
Takeda Pharmaceutical Company Limited |
Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
|
|
TW202515531A
(zh)
|
2023-07-07 |
2025-04-16 |
美商輝瑞股份有限公司 |
兩親性tlr7/8佐劑及其用途
|
|
CN121532514A
(zh)
|
2023-07-07 |
2026-02-13 |
上海环码生物医药有限公司 |
用于季节性流感的环状rna疫苗及使用方法
|
|
AU2024287308A1
(en)
|
2023-07-13 |
2025-12-18 |
Korro Bio, Inc. |
Rna-editing oligonucleotides and uses thereof
|
|
WO2025015338A1
(en)
|
2023-07-13 |
2025-01-16 |
Korro Bio, Inc. |
Rna-editing oligonucleotides and uses thereof
|
|
WO2025016294A1
(zh)
|
2023-07-14 |
2025-01-23 |
云合智药(苏州)生物科技有限公司 |
用于抑制己酮糖激酶表达的RNAi剂及其应用
|
|
WO2025024324A1
(en)
|
2023-07-21 |
2025-01-30 |
BioNTech SE |
Compositions for delivery of plasmodium antigens and related methods
|
|
WO2025024335A2
(en)
|
2023-07-21 |
2025-01-30 |
BioNTech SE |
Compositions for delivery of plasmodium antigens and related methods
|
|
AU2024299365A1
(en)
|
2023-07-24 |
2026-01-08 |
BioNTech SE |
Compositions for delivery of plasmodium antigens and related methods
|
|
WO2025021083A1
(en)
*
|
2023-07-24 |
2025-01-30 |
National Institute Of Biological Sciences, Beijing |
Lipid nanoparticle compositions for localized treatment of skin diseases
|
|
AU2024299627A1
(en)
|
2023-07-25 |
2026-01-22 |
Flagship Pioneering Innovations Vii, Llc |
Cas endonucleases and related methods
|
|
WO2025022367A2
(en)
|
2023-07-27 |
2025-01-30 |
Life Edit Therapeutics, Inc. |
Rna-guided nucleases and active fragments and variants thereof and methods of use
|
|
TW202519509A
(zh)
|
2023-08-01 |
2025-05-16 |
德商拜恩技術股份公司 |
可離子化硫脂質及其用途
|
|
WO2025026545A1
(en)
|
2023-08-01 |
2025-02-06 |
BioNTech SE |
Ionizable thioplipids and uses thereof
|
|
AU2024316307A1
(en)
|
2023-08-03 |
2026-02-26 |
BioNTech SE |
Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
|
|
WO2025027579A2
(en)
|
2023-08-03 |
2025-02-06 |
BioNTech SE |
Rna compositions targeting hiv
|
|
WO2025027576A2
(en)
|
2023-08-03 |
2025-02-06 |
BioNTech SE |
Rna compositions targeting hiv
|
|
WO2025030154A1
(en)
|
2023-08-03 |
2025-02-06 |
The Trustees Of The University Of Pennsylvania |
Pharmaceutical compositions for delivery of herpes simplex virus glycoprotein b antigens and related methods
|
|
NL2035538B1
(en)
|
2023-08-03 |
2025-02-18 |
Univ Eindhoven Tech |
Lipid-like copolymers and method of producing these and the use thereof, pharmaceutical compositions comprising said copolymers, and the use of said compositions.
|
|
WO2025034422A1
(en)
|
2023-08-04 |
2025-02-13 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating ctnnb1-associated disorders
|
|
US12162927B1
(en)
|
2023-08-09 |
2024-12-10 |
Wyvern Pharmaceuticals Inc. |
Compositions and methods for regulating production of an antibody like protein and ribonucleic acid
|
|
WO2025042786A1
(en)
|
2023-08-18 |
2025-02-27 |
Flagship Pioneering Innovations Vi, Llc |
Compositions comprising circular polyribonucleotides and uses thereof
|
|
WO2025045767A1
(en)
|
2023-08-25 |
2025-03-06 |
Ethris Gmbh |
Stabilized lipid and lipidoid nanoparticle formulations with specific surfactant properties for enhanced pharmaceutical applications
|
|
WO2025049690A1
(en)
|
2023-08-29 |
2025-03-06 |
Orna Therapeutics, Inc. |
Circular polyethylene glycol lipids
|
|
WO2025045142A1
(en)
|
2023-08-29 |
2025-03-06 |
Shanghai Circode Biomed Co., Ltd. |
Circular rna encoding vegf polypeptides, formulations, and methods of uses
|
|
WO2025049959A2
(en)
|
2023-09-01 |
2025-03-06 |
Renagade Therapeutics Management Inc. |
Gene editing systems, compositions, and methods for treatment of vexas syndrome
|
|
WO2025046121A1
(en)
|
2023-09-01 |
2025-03-06 |
Novoarc Gmbh |
Lipid nanoparticle with nucleic acid cargo and ionizable lipid
|
|
EP4520345A1
(en)
|
2023-09-06 |
2025-03-12 |
Myneo Nv |
Product
|
|
WO2025054236A2
(en)
|
2023-09-06 |
2025-03-13 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
WO2025052180A2
(en)
|
2023-09-07 |
2025-03-13 |
Axelyf ehf. |
Lipids and lipid nanoparticles
|
|
WO2025054556A1
(en)
|
2023-09-07 |
2025-03-13 |
BioNTech SE |
Rna compositions for delivery of mpox antigens and related methods
|
|
WO2025051994A1
(en)
|
2023-09-07 |
2025-03-13 |
Coave Therapeutics |
Ionizable lipid nanoparticles
|
|
WO2025057088A1
(en)
|
2023-09-11 |
2025-03-20 |
BioNTech SE |
Rna compositions for delivery of incretin agents
|
|
TW202525266A
(zh)
|
2023-09-18 |
2025-07-01 |
美商旗艦先鋒創新有限責任(Vii)公司 |
可電離類脂質組成物及其治療用途
|
|
WO2025064660A2
(en)
|
2023-09-21 |
2025-03-27 |
Alnylam Pharmaceuticals, Inc. |
Activin a receptor type 1c (acvr1c) irna compositions and methods of use thereof
|
|
WO2025064850A1
(en)
|
2023-09-22 |
2025-03-27 |
BioNTech SE |
Rna constructs with n-terminal degrons to enhance an immune response
|
|
WO2025072383A1
(en)
|
2023-09-25 |
2025-04-03 |
The Broad Institute, Inc. |
Viral open reading frames, uses thereof, and methods of detecting the same
|
|
WO2025072331A1
(en)
|
2023-09-26 |
2025-04-03 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
AU2024352437A1
(en)
|
2023-09-27 |
2026-03-19 |
Resolution Therapeutics Limited |
Therapeutic macrophages
|
|
WO2025072672A2
(en)
|
2023-09-27 |
2025-04-03 |
Judo Bio, Inc. |
Slc6a19-targeting modulatory nucleic acid agents
|
|
WO2025072713A1
(en)
|
2023-09-27 |
2025-04-03 |
Judo Bio, Inc. |
Polymyxins for delivery of agents to the kidney
|
|
WO2025072293A1
(en)
|
2023-09-27 |
2025-04-03 |
Scribe Therapeutics Inc. |
Optimized mrnas encoding casx proteins
|
|
WO2025072699A1
(en)
|
2023-09-27 |
2025-04-03 |
Judo Bio, Inc. |
Aminoglycosides for delivery of agents to the kidney
|
|
WO2025076031A2
(en)
|
2023-10-03 |
2025-04-10 |
Alnylam Pharmaceuticals, Inc. |
Peritoneal macrophages comprising a nanoparticle encapsulating a nucleic acid molecule and methods of use thereof
|
|
WO2025081042A1
(en)
|
2023-10-12 |
2025-04-17 |
Renagade Therapeutics Management Inc. |
Nickase-retron template-based precision editing system and methods of use
|
|
WO2025083619A1
(en)
|
2023-10-18 |
2025-04-24 |
Life Edit Therapeutics, Inc. |
Rna-guided nucleases and acive fragments and variants thereof and methods of use
|
|
WO2025096807A2
(en)
|
2023-10-31 |
2025-05-08 |
Flagship Pioneering Innovations Vii, Llc |
Novel therapeutic dna forms
|
|
WO2025097055A2
(en)
|
2023-11-02 |
2025-05-08 |
The Broad Institute, Inc. |
Compositions and methods of use of t cells in immunotherapy
|
|
WO2025101501A1
(en)
|
2023-11-07 |
2025-05-15 |
Orna Therapeutics, Inc. |
Circular rna compositions
|
|
WO2025106670A1
(en)
|
2023-11-14 |
2025-05-22 |
Flagship Pioneering Innovations Vii, Llc |
Ionizable lipidoid compositions and therapeutic uses thereof
|
|
TW202539697A
(zh)
|
2023-11-15 |
2025-10-16 |
德商拜恩技術股份公司 |
冠狀病毒疫苗
|
|
US12435338B2
(en)
|
2023-11-22 |
2025-10-07 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
US12195747B1
(en)
|
2023-11-22 |
2025-01-14 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
WO2025111526A1
(en)
|
2023-11-22 |
2025-05-30 |
Flagship Pioneering Innovations Vii, Llc |
Methods and compositions for treating non-alcoholic fatty liver disease
|
|
US12522830B2
(en)
|
2023-11-22 |
2026-01-13 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
US12559754B2
(en)
|
2023-11-22 |
2026-02-24 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
WO2025114520A1
(en)
|
2023-12-01 |
2025-06-05 |
Coave Therapeutics |
Ionizable lipid nanoparticles
|
|
WO2025128799A1
(en)
|
2023-12-12 |
2025-06-19 |
Korro Bio, Inc. |
Double-stranded rna-editing oligonucleotides and uses thereof
|
|
WO2025124711A1
(en)
|
2023-12-13 |
2025-06-19 |
BioNTech SE |
Glycolipid compositions
|
|
WO2025128871A2
(en)
|
2023-12-13 |
2025-06-19 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2025129158A1
(en)
|
2023-12-15 |
2025-06-19 |
The Broad Institute, Inc. |
Engineered arc delivery vesicles and uses thereof
|
|
US20250332281A2
(en)
|
2023-12-15 |
2025-10-30 |
Capstan Therapeutics, Inc. |
Humanized anti-cd8 antibodies and uses thereof
|
|
WO2025134066A1
(en)
|
2023-12-21 |
2025-06-26 |
Biontech Delivery Technologies Gmbh |
Ionizable lipids
|
|
TW202525287A
(zh)
|
2023-12-21 |
2025-07-01 |
德商拜恩技術運輸科技有限責任公司 |
可離子化脂質
|
|
WO2025133105A1
(en)
|
2023-12-21 |
2025-06-26 |
Biontech Delivery Technologies Gmbh |
Compositions and methods
|
|
WO2025132839A1
(en)
|
2023-12-21 |
2025-06-26 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2025144938A1
(en)
|
2023-12-26 |
2025-07-03 |
Emmune, Inc. |
Systems for nucleic acid transfer
|
|
WO2025140551A1
(en)
|
2023-12-29 |
2025-07-03 |
Neuro3 Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR TREATING NaV1.7 (SCN9A) -ASSOCIATED DISORDERS
|
|
WO2025149492A1
(en)
|
2024-01-08 |
2025-07-17 |
BioNTech SE |
Rna encoding an immune inhibitory il-1 family member
|
|
WO2025155753A2
(en)
|
2024-01-17 |
2025-07-24 |
Renagade Therapeutics Management Inc. |
Improved gene editing system, guides, and methods
|
|
KR102716110B1
(ko)
|
2024-01-19 |
2024-10-15 |
(주) 멥스젠 |
다양한 크기를 갖는 지질나노입자 제조용 미세유체장치 및 이를 이용한 제조방법
|
|
WO2025160334A1
(en)
|
2024-01-26 |
2025-07-31 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025166238A1
(en)
|
2024-01-31 |
2025-08-07 |
Orna Therapeutics, Inc. |
Fast-shedding polyethylene glycol lipids
|
|
WO2025166325A1
(en)
|
2024-02-02 |
2025-08-07 |
Editas Medicine, Inc. |
MODIFIED GUIDE RNAs
|
|
WO2025174908A1
(en)
|
2024-02-12 |
2025-08-21 |
Life Edit Therapeutics, Inc. |
Novel rna-guided nucleases and proteins for polymerase editing
|
|
WO2025174765A1
(en)
|
2024-02-12 |
2025-08-21 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
US12522831B2
(en)
|
2024-02-20 |
2026-01-13 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
US12416020B2
(en)
|
2024-02-20 |
2025-09-16 |
Wyvern Pharmaceuticals Inc. |
Plasmid encoding a TLR3 and Fc fusion protein
|
|
US12540324B2
(en)
|
2024-02-20 |
2026-02-03 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
US12281311B1
(en)
|
2024-02-20 |
2025-04-22 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
WO2025184508A1
(en)
|
2024-03-01 |
2025-09-04 |
Acuitas Therapeutics, Inc. |
Materials and methods for encapsulating therapeutics in lipid nanoparticles
|
|
WO2025194019A1
(en)
|
2024-03-14 |
2025-09-18 |
Flagship Pioneering Innovations Vii, Llc |
Methods for treating liver fibrosis and non-alcoholic fatty liver disease
|
|
WO2025194138A1
(en)
|
2024-03-14 |
2025-09-18 |
Tessera Therapeutics, Inc. |
St1cas9 compositions and methods for modulating a genome
|
|
WO2025199231A2
(en)
|
2024-03-20 |
2025-09-25 |
Vertex Pharmaceuticals Incorporated |
Mucin-5b (muc5b) targeted sirna and antisense oligonucleotides and methods of use thereof
|
|
WO2025202287A1
(en)
|
2024-03-26 |
2025-10-02 |
Resolution Therapeutics Limited |
Method of producing macrophages
|
|
WO2025202937A1
(en)
|
2024-03-26 |
2025-10-02 |
BioNTech SE |
Cancer vaccines
|
|
GB202404607D0
(en)
|
2024-03-29 |
2024-05-15 |
Glaxosmithkline Biologicals Sa |
RNA formulation
|
|
WO2025213138A1
(en)
|
2024-04-05 |
2025-10-09 |
Editas Medicine, Inc. |
Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma
|
|
WO2025213131A1
(en)
|
2024-04-05 |
2025-10-09 |
BioNTech SE |
Rna compositions for delivery of orthopox antigens and related methods
|
|
WO2025217275A2
(en)
|
2024-04-10 |
2025-10-16 |
Flagship Pioneering Innovations Vii, Llc |
Immune cell targeted compositions and related methods
|
|
WO2025219570A1
(en)
|
2024-04-17 |
2025-10-23 |
Johannes Kepler Universität Linz |
Composition for inhibiting protein translocation and methods using the same
|
|
KR20250157196A
(ko)
*
|
2024-04-26 |
2025-11-04 |
한국과학기술원 |
핵산 분자의 흡입 전달용 지질 나노복합체
|
|
WO2025228975A1
(en)
|
2024-04-29 |
2025-11-06 |
BioNTech SE |
Particles, compositions and methods
|
|
WO2025235862A1
(en)
|
2024-05-10 |
2025-11-13 |
Inndura Therapeutics Inc. |
A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a
|
|
WO2025240680A1
(en)
|
2024-05-16 |
2025-11-20 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025240940A1
(en)
|
2024-05-17 |
2025-11-20 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of apolipoprotein c3
|
|
WO2025245188A2
(en)
|
2024-05-21 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Methods of treating liver steatosis and non-alcoholic fatty liver disease
|
|
WO2025245111A1
(en)
|
2024-05-22 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor targeting proteins and related methods
|
|
WO2025250808A1
(en)
|
2024-05-29 |
2025-12-04 |
The Brigham And Women’S Hospital, Inc. |
Anti-crispr delivery compositions and methods
|
|
WO2025259747A2
(en)
|
2024-06-12 |
2025-12-18 |
Alnylam Pharmaceuticals, Inc. |
Dystrophy myotonic protein kinase (dmpk) irna compositions and methods of use thereof
|
|
WO2025262460A1
(en)
|
2024-06-21 |
2025-12-26 |
BioNTech SE |
Lipid compositions for nucleic acid delivery
|
|
WO2026003754A1
(en)
|
2024-06-25 |
2026-01-02 |
Life Edit Therapeutics, Inc. |
Novel reverse transcriptases and uses thereof
|
|
US20260000702A1
(en)
|
2024-06-26 |
2026-01-01 |
Flagship Pioneering Innovations Vii, Llc |
Therapeutic circular dna forms
|
|
WO2026003582A2
(en)
|
2024-06-27 |
2026-01-02 |
Axelyf ehf. |
Lipids and lipid nanoparticles
|
|
WO2026015882A1
(en)
|
2024-07-12 |
2026-01-15 |
BioNTech SE |
Hsv antigen fragments and related methods
|
|
WO2026018213A1
(en)
|
2024-07-18 |
2026-01-22 |
Vaxthera Sas |
A broadly protective mosaic vaccine against highly pathogenic avian influenza viruses
|
|
WO2026020171A2
(en)
|
2024-07-19 |
2026-01-22 |
Aera Therapeutics, Inc. |
Chimeric antigen receptor constructs
|
|
WO2026022652A1
(en)
|
2024-07-22 |
2026-01-29 |
Waters Technologies Corporation |
Methods for analyzing lipid nanoparticles and uses thereof
|
|
WO2026024954A2
(en)
|
2024-07-24 |
2026-01-29 |
Altos Labs, Inc. |
Use of regeneration factors in organ transplantation
|
|
WO2026027887A2
(en)
|
2024-08-02 |
2026-02-05 |
Mina Therapeutics Limited |
Hbg1/2-sarna compositions and methods of use
|
|
WO2026047603A1
(en)
|
2024-08-28 |
2026-03-05 |
BioNTech SE |
Sars-cov-2 immunogenic compositions
|
|
US12570983B2
(en)
|
2024-08-30 |
2026-03-10 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
WO2026055461A1
(en)
|
2024-09-05 |
2026-03-12 |
Aperture Therapeutics, Inc. |
Antibody oligonucleotide conjugates comprising an antisense polynucleotide agent conjugated to a cd33 antibody and methods of use thereof
|
|
WO2026055547A1
(en)
|
2024-09-06 |
2026-03-12 |
Flagship Pioneering Innovations Vii, Llc |
Dna compositions and related methods
|
|
WO2026055543A1
(en)
|
2024-09-06 |
2026-03-12 |
Flagship Pioneering Innovations Vii, Llc |
Modified dna compositions and related methods
|
|
US12480129B1
(en)
|
2024-09-17 |
2025-11-25 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
US12509688B1
(en)
|
2024-09-17 |
2025-12-30 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
US12486506B1
(en)
|
2024-09-20 |
2025-12-02 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
US12545917B1
(en)
|
2024-09-20 |
2026-02-10 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
US12480121B1
(en)
|
2024-09-20 |
2025-11-25 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
US12480123B1
(en)
|
2024-09-20 |
2025-11-25 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
US12503702B1
(en)
|
2024-09-25 |
2025-12-23 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
US12416021B1
(en)
|
2024-10-11 |
2025-09-16 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of proteins
|
|
US12428654B1
(en)
|
2024-10-29 |
2025-09-30 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of proteins
|
|
US12416022B1
(en)
|
2024-10-29 |
2025-09-16 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of proteins
|
|
US12529059B1
(en)
|
2024-12-12 |
2026-01-20 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
US12509694B1
(en)
|
2024-12-12 |
2025-12-30 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
US12553046B1
(en)
|
2025-02-11 |
2026-02-17 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
US12565652B1
(en)
|
2025-03-27 |
2026-03-03 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
US12497618B1
(en)
|
2025-09-09 |
2025-12-16 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
CN121466311A
(zh)
*
|
2026-01-09 |
2026-02-06 |
羿美诚健(上海)生物医药有限公司 |
一种脂质组合物及其在核酸递送中的应用
|